Updated on 2024/04/11

写真a

 
TSUJI Kenji
 
Organization
Faculty of Medicine, Dentistry and Pharmaceutical Sciences Assistant Professor
Position
Assistant Professor
External link

Degree

  • 博士(医学) ( 2014.9   岡山大学 )

  • 学士(医学) ( 2006.3   岡山大学 )

Research Interests

  • Dialysis

  • Regeneration

  • 腎臓発生

  • 腎臓線維化

  • 急性腎障害

  • 慢性腎臓病

Research Areas

  • Life Science / Clinical pharmacy  / 腎臓生理学

  • Life Science / Pathological biochemistry  / 腎線維化

  • Life Science / Nephrology  / 急性腎障害

  • Life Science / Physiology  / 腎臓生理学

  • Life Science / Anatomy  / 腎臓発生・再生

Education

  • Okayama University   病態制御科学専攻  

    2010.4 - 2014.9

      More details

  • Okayama University   医学部   医学科

    2000.4 - 2006.3

      More details

Research History

  • 岡山大学大学院医歯薬学総合研究科   助教

    2018.4

      More details

  • 三豊総合病院   医長

    2017.10 - 2018.3

      More details

  • 岡山大学大学院医歯薬学総合研究科   客員研究員

    2017.10 - 2018.3

      More details

  • マサチューセッツ総合病院   博士研究員

    2014.10 - 2017.9

      More details

  • Okayama University   Graduate School of Medicine , Dentistry and Pharmaceutical Sciences, Biopathological Sciences

    2010.4 - 2014.9

      More details

  • Okayama University   腎臓・糖尿病・内分泌代謝内科

    2010.4 - 2011.3

      More details

  • 愛媛県立中央病院   腎臓内科専攻医

    2008.4 - 2010.3

      More details

  • 愛媛県立中央病院   研修医

    2006.4 - 2008.3

      More details

▼display all

Professional Memberships

  • 日本腎病理協会

    2021.12

      More details

  • 日本腎臓病協会

    2020.2

      More details

  • THE JAPANESE SOCIETY FOR DIALYSIS THERAPY

    2009.2

      More details

  • JAPANESE SOCIETY OF NEPHROLOGY

    2008.2

      More details

  • THE JAPANESE SOCIETY OF INTERNAL MEDICINE

    2006.8

      More details

Committee Memberships

  • 日本腎臓学会   腎臓専門医試験症例評価委員会委員  

    2024.1   

      More details

  •   第54回日本腎臓学会西部学術大会プログラム委員  

    2023.11   

      More details

  •   日本腎臓病協会 試験認定小委員会委員  

    2023.10   

      More details

  •   日本内科学会中国支部評議員  

    2023.5   

      More details

  • 日本腎臓学会   評議員  

    2022.4   

      More details

  • 日本透析医学会   指導医  

    2021.4   

      More details

    Committee type:Academic society

    researchmap

  • 日本内科学会   指導医  

    2020.7   

      More details

  •   日本腎臓学会 指導医  

    2019.4   

      More details

    Committee type:Academic society

    researchmap

  •   日本腎臓学会 サポーター認定  

    2019.3   

      More details

  • 日本内科学会   総合内科専門医  

    2018.12   

      More details

    Committee type:Academic society

    researchmap

  • 日本透析医学会   専門医  

    2014.4   

      More details

    Committee type:Academic society

    researchmap

  • 日本腎臓学会   専門医  

    2013.4   

      More details

    Committee type:Academic society

    researchmap

  • 日本内科学会   認定内科医  

    2010.9   

      More details

    Committee type:Academic society

    researchmap

▼display all

 

Papers

  • Effects of HIF-PHD inhibitors in kidney development. Reviewed International journal

    Soichiro Haraguchi, Kenji Tsuji, Hiroyuki Nakanoh, Kazuhiko Fukushima, Shinji Kitamura, Jun Wada

    Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association   2024.3

     More details

    Authorship:Corresponding author   Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1093/ndt/gfae078

    PubMed

    researchmap

  • Kidney Veno-Muscular Characteristics and Kidney Disease Progression: A Native Kidney-Biopsy Study. Reviewed International journal

    Kenji Tsuji, Hiroyuki Nakanoh, Kensaku Takahashi, Takafumi Morita, Yizhen Sang, Kazuhiko Fukushima, Natsumi Matsuoka-Uchiyama, Yasuhiro Onishi, Haruhito A Uchida, Shinji Kitamura, Jun Wada

    Kidney medicine   5 ( 12 )   100733 - 100733   2023.12

     More details

    Authorship:Lead author, Corresponding author   Language:English   Publishing type:Research paper (scientific journal)  

    RATIONALE & OBJECTIVE: Assessment of kidney biopsies provides crucial information for diagnosis and disease activity, as well as prognostic value. Kidney-biopsy specimens occasionally contain veno-muscular complex (VMC), which consists of muscle tissues around the kidney venous system in the corticomedullary region. However, the role of VMC and the clinical significance of VMC variants are poorly understood. In the present study, we investigated kidney prognostic values of VMC variants. STUDY DESIGN: Retrospective cohort study. SETTING & PARTICIPANTS: Among 808 patients who underwent a kidney biopsy from 2011 to 2019, 246 patients whose kidney biopsy specimens contained VMC were enrolled. PREDICTORS: VMC variants; inflammatory-VMC (an infiltration of ≥80 inflammatory cells/mm2-VMC area) and VMC hypertrophy (hyper-VMC, a VMC average width ≥850 μm), and the interstitial fibrosis/tubular atrophy (IFTA) score. OUTCOMES: A decline in estimated glomerular filtration rate (eGFR) ≥40% from the baseline or commencement of kidney replacement therapy. ANALYTICAL APPROACH: Cox proportional hazards model. RESULTS: Among 246 patients with data on VMC, mean baseline eGFR was 56.0±25.6 ml/min per 1.73 m2; 80 had high inflammatory-VMC, and 62 had VMC hypertrophy. There were 51 kidney events over median follow-up of 2.5 years. We analyzed 2 VMC variants. Multivariable logistic regression analysis revealed that eGFR negatively correlated with the presence of both inflammatory-VMC and hyper-VMC. A Cox proportional hazards analysis revealed that inflammatory-VMC (but not hyper-VMC) was independently associated with the primary outcome after adjustments for known risk factors of progression, including proteinuria, eGFR, and the interstitial fibrosis/tubular atrophy (IFTA) score (hazard ratio, 1.97; 95% confidence interval, 1.00-3.91). LIMITATIONS: Single-center study and small sample size. CONCLUSIONS: Assessment of inflammatory-VMC provides additional kidney prognostic information to known indicators of kidney disease progression in patients who undergo kidney biopsy. PLAIN-LANGUAGE SUMMARY: Assessment of kidney biopsies provides crucial information for diagnosis, disease activity, and prognostic value. Kidney-biopsy specimens occasionally contain veno-muscular complex (VMC), which consists of muscle tissues around the kidney venous system. Currently, the role of VMC in kidney health and diseases and the clinical significance of VMC variants are poorly understood. In the present study, we have shown that an infiltration of ≥80 inflammatory cells/mm2-VMC area (inflammatory-VMC) is independently associated with kidney disease progression after adjustments for known risk factors of progression. Therefore, assessment of inflammatory-VMC provides additional kidney prognostic information to known indicators of kidney disease progression in patients who undergo kidney biopsy.

    DOI: 10.1016/j.xkme.2023.100733

    PubMed

    researchmap

  • Preventive effect of culture supernatant of epithelial-like peritoneal mesothelial cells on peritoneal fibrosis. Reviewed International journal

    Kensaku Takahashi, Kenji Tsuji, Hiroyuki Nakanoh, Kazuhiko Fukushima, Shinji Kitamura, Jun Wada

    Peritoneal dialysis international : journal of the International Society for Peritoneal Dialysis   8968608231213577 - 8968608231213577   2023.11

     More details

    Authorship:Corresponding author   Language:English   Publishing type:Research paper (scientific journal)  

    Peritoneal fibrosis (PF) is a primary reason for discontinuing peritoneal dialysis, which involves characteristic changes of peritoneal mesothelial cells (PMCs). We previously reported preventive effects of implanting human epithelial-like PMCs (P-Epi) for mouse PF caused by mechanical peritoneum scrapings. In the present study, we analysed the preventive effects of culture supernatant of P-Epi in PF. Concentrated culture supernatant of P-Epi or human fibroblast-like PMCs (P-Fibro) or vehicles was injected into nude mice that had undergone mechanical scraping of the parietal and visceral peritoneum, and thickness and amount of adhesions were analysed. Although increased peritoneal adhesions and peritoneum thickening were observed in the vehicle-injected positive control group compared to the sham operation group, fewer number of adhesions and less thickness were observed in the mice treated with culture supernatant of P-Epi, but not P-Fibro, compared to the vehicle-injected positive controls. Immunofluorescent analysis revealed that the expression of extracellular matrix, type I collagen and fibronectin, was lower in the mice treated with culture supernatant of P-Epi than in the vehicle-injected positive controls. In addition, exosomes from P-Epi significantly reduced transforming growth factor-β (TGF-β)-induced expressions of type I collagen and fibronectin in 3T3 fibroblast cells. Collectively, culture supernatant of P-Epi has preventive effects on PF, thus cell therapy is not necessarily required. Further exploration of substances secreted by P-Epi and their protective mechanisms could lead to the development of therapeutic strategies to limit PF.

    DOI: 10.1177/08968608231213577

    PubMed

    researchmap

  • Role of Semaphorin 3A in Kidney Development and Diseases. Reviewed International journal

    Yizhen Sang, Kenji Tsuji, Hiroyuki Nakanoh, Kazuhiko Fukushima, Shinji Kitamura, Jun Wada

    Diagnostics (Basel, Switzerland)   13 ( 19 )   2023.9

     More details

    Authorship:Corresponding author   Language:English   Publishing type:Research paper (scientific journal)  

    Kidney diseases are worldwide public health problems affecting millions of people. However, there are still limited therapeutic options against kidney diseases. Semaphorin 3A (SEMA3A) is a secreted and membrane-associated protein, which regulates diverse functions, including immune regulation, cell survival, migration and angiogenesis, thus involving in the several pathogeneses of diseases, including eyes and neurons, as well as kidneys. SEMA3A is expressed in podocytes and tubular cells in the normal adult kidney, and recent evidence has revealed that excess SEMA3A expression and the subsequent signaling pathway aggravate kidney injury in a variety of kidney diseases, including nephrotic syndrome, diabetic nephropathy, acute kidney injury, and chronic kidney disease. In addition, several reports have demonstrated that the inhibition of SEMA3A ameliorated kidney injury via a reduction in cell apoptosis, fibrosis and inflammation; thus, SEMA3A may be a potential therapeutic target for kidney diseases. In this review article, we summarized the current knowledge regarding the role of SEMA3A in kidney pathophysiology and their potential use in kidney diseases.

    DOI: 10.3390/diagnostics13193038

    PubMed

    researchmap

  • MicroRNAs as Biomarkers and Therapeutic Targets for Acute Kidney Injury. Reviewed International journal

    Kenji Tsuji, Hiroyuki Nakanoh, Kazuhiko Fukushima, Shinji Kitamura, Jun Wada

    Diagnostics (Basel, Switzerland)   13 ( 18 )   2023.9

     More details

    Authorship:Lead author, Corresponding author   Language:English   Publishing type:Research paper (scientific journal)  

    Acute kidney injury (AKI) is a clinical syndrome where a rapid decrease in kidney function and/or urine output is observed, which may result in the imbalance of water, electrolytes and acid base. It is associated with poor prognosis and prolonged hospitalization. Therefore, an early diagnosis and treatment to avoid the severe AKI stage are important. While several biomarkers, such as urinary L-FABP and NGAL, can be clinically useful, there is still no gold standard for the early detection of AKI and there are limited therapeutic options against AKI. miRNAs are non-coding and single-stranded RNAs that silence their target genes in the post-transcriptional process and are involved in a wide range of biological processes. Recent accumulated evidence has revealed that miRNAs may be potential biomarkers and therapeutic targets for AKI. In this review article, we summarize the current knowledge about miRNAs as promising biomarkers and potential therapeutic targets for AKI, as well as the challenges in their clinical use.

    DOI: 10.3390/diagnostics13182893

    PubMed

    researchmap

  • Elderly Brothers With Fabry Disease Exhibiting Cardiac and Renal Manifestations Reviewed

    Keiko Tanaka, Hitoshi Sugiyama, Hiroshi Morinaga, Akifumi Onishi, Yuzuki Kano, Hidemi Takeuchi, Kenji Tsuji, Motoki Kubo, Katsuyuki Tanabe, Haruhito A. Uchida, Kazufumi Nakamura, Jun Wada

    Annals of Internal Medicine: Clinical Cases   2 ( 5 )   2023.5

     More details

    Publishing type:Research paper (scientific journal)   Publisher:American College of Physicians  

    DOI: 10.7326/aimcc.2022.1003

    researchmap

  • The Effect of Medical Cooperation in the CKD Patients: 10-Year Multicenter Cohort Study. Reviewed International journal

    Yasuhiro Onishi, Haruhito A Uchida, Yohei Maeshima, Yuka Okuyama, Nozomu Otaka, Haruyo Ujike, Keiko Tanaka, Hidemi Takeuchi, Kenji Tsuji, Masashi Kitagawa, Katsuyuki Tanabe, Hiroshi Morinaga, Masaru Kinomura, Shinji Kitamura, Hitoshi Sugiyama, Kosuke Ota, Keisuke Maruyama, Makoto Hiramatsu, Yoshiyuki Oshiro, Shigeru Morioka, Keiichi Takiue, Kazuyoshi Omori, Masaki Fukushima, Naoyuki Gamou, Hiroshi Hirata, Ryosuke Sato, Hirofumi Makino, Jun Wada

    Journal of personalized medicine   13 ( 4 )   2023.3

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    INTRODUCTION: While chronic kidney disease (CKD) is one of the most important contributors to mortality from non-communicable diseases, the number of nephrologists is limited worldwide. Medical cooperation is a system of cooperation between primary care physicians and nephrological institutions, consisting of nephrologists and multidisciplinary care teams. Although it has been reported that multidisciplinary care teams contribute to the prevention of worsening renal functions and cardiovascular events, there are few studies on the effect of a medical cooperation system. METHODS: We aimed to evaluate the effect of medical cooperation on all-cause mortality and renal prognosis in patients with CKD. One hundred and sixty-eight patients who visited the one hundred and sixty-three clinics and seven general hospitals of Okayama city were recruited between December 2009 and September 2016, and one hundred twenty-three patients were classified into a medical cooperation group. The outcome was defined as the incidence of all-cause mortality, or renal composite outcome (end-stage renal disease or 50% eGFR decline). We evaluated the effects on renal composite outcome and pre-ESRD mortality while incorporating the competing risk for the alternate outcome into a Fine-Gray subdistribution hazard model. RESULTS: The medical cooperation group had more patients with glomerulonephritis (35.0% vs. 2.2%) and less nephrosclerosis (35.0% vs. 64.5%) than the primary care group. Throughout the follow-up period of 5.59 ± 2.78 years, 23 participants (13.7%) died, 41 participants (24.4%) reached 50% decline in eGFR, and 37 participants (22.0%) developed end-stage renal disease (ESRD). All-cause mortality was significantly reduced by medical cooperation (sHR 0.297, 95% CI 0.105-0.835, p = 0.021). However, there was a significant association between medical cooperation and CKD progression (sHR 3.069, 95% CI 1.225-7.687, p = 0.017). CONCLUSION: We evaluated mortality and ESRD using a CKD cohort with a long-term observation period and concluded that medical cooperation might be expected to influence the quality of medical care in the patients with CKD.

    DOI: 10.3390/jpm13040582

    PubMed

    researchmap

  • スチレン系軟質樹脂を用いた腎生検シミュレーターの開発と有用性の検討 Reviewed

    辻 憲二, 喜多村 真治, 和田 淳

    日本腎臓学会誌   65 ( 2 )   105 - 111   2023.3

     More details

    Authorship:Lead author, Corresponding author   Language:Japanese   Publisher:(一社)日本腎臓学会  

    超音波ガイド経皮的針腎生検は,種々の腎臓病の診断および活動性の評価のために必要な検査であるが,出血などの合併症のリスクが高い侵襲的な技術であり,実用的なシミュレーションモデルが望まれる。われわれは鶏卵を用いた簡易的腎生検シミュレーターを開発したが,耐久性が低く長期保存が困難であった。今回われわれは幅広く適用されるモデルを目指して,スチレン系軟質樹脂を用いた新たな腎生検シミュレーターを開発した。作製したモデルは,超音波下で腎臓の皮質・髄質に該当する部分のコントラストは実際の腎臓のものに類似しており,針穿刺の際にモデル内に針が侵入する様子が超音波下で観察可能であった。本モデルの検証のため,岡山大学病院の腎生検経験20例未満の研修生10名に腎生検模擬を実施し,腎生検経験20例以上の腎生検に熟達した腎臓内科医20名がその様子を観察あるいは模擬を実施した。また,腎生検模擬後に全参加者にアンケート調査を実施した。90%の研修生が,今回の腎生検模擬によって患者への腎生検に対する不安が軽減されると回答した。また,すべての参加者が,研修生が本腎生検模擬を行うことを推奨すると回答した。耐久性の評価では,約100回穿刺後の形態および超音波下の画像ともに継続使用可能と考えられた。以上から,開発したシミュレーターは腎生検の実用的なシミュレーションモデルの良い候補になり得る。(著者抄録)

    researchmap

  • Association between Urinary Creatinine Excretion and Hypothyroidism in Patients with Chronic Kidney Disease. Reviewed International journal

    Natsumi Matsuoka-Uchiyama, Kenji Tsuji, Kensaku Takahashi, Kazuhiko Fukushima, Hidemi Takeuchi, Shinji Kitamura, Kenichi Inagaki, Haruhito A Uchida, Jun Wada

    Diagnostics (Basel, Switzerland)   13 ( 4 )   2023.2

     More details

    Authorship:Corresponding author   Language:English   Publishing type:Research paper (scientific journal)  

    While hypothyroidism increases serum creatinine (Cr) levels, it is uncertain whether the elevation is mediated via a decline in the glomerular filtration rate (GFR) or the reflection of enhanced Cr production from the muscles or both. In the present study, we explored an association between urinary Cr excretion rate (CER) and hypothyroidism. A total of 553 patients with chronic kidney disease were enrolled in a cross-sectional study. Multiple linear regression analysis was performed to explore the association between hypothyroidism and urinary CER. The mean urinary CER was 1.01 ± 0.38 g/day and 121 patients (22%) had hypothyroidism. The multiple linear regression analysis revealed explanatory variables with urinary CER, including age, sex, body mass index, 24 h Cr clearance (24hrCcr), and albumin while hypothyroidism was not considered an independent explanatory variable. In addition, scatter plot analysis with regression fit line representing the association between estimated GFR calculated using s-Cr (eGFRcre) and 24hrCcr revealed that eGFRcre and 24hrCcr had strong correlations with each other in hypothyroid patients as well as euthyroid patients. Collectively, hypothyroidism was not considered an independent explanatory variable for urinary CER in the present study and eGFRcre is a useful marker to evaluate kidney function regardless of the presence of hypothyroidism.

    DOI: 10.3390/diagnostics13040669

    PubMed

    researchmap

  • 慢性腎臓病におけるSemaphorin3Aを介した腎臓線維化の制御

    辻 憲二

    日本透析医会雑誌   37 ( 3 )   533 - 536   2022.12

     More details

    Authorship:Lead author, Corresponding author   Language:Japanese   Publisher:(公社)日本透析医会  

    腎臓線維化は慢性腎臓病進展における共通経路として知られるが,治療法は限られており,新規機序の薬物創出が求められている.Semaphorin3A(SEMA3A)は細胞間の情報伝達物質として機能する分泌型蛋白であり,細胞増殖,血管新生,免疫細胞の制御など多彩な生理活性作用を持つ.SEMA3Aは腎臓では糸球体上皮細胞および尿細管上皮細胞に発現し,腎臓病進展との関連性が報告されるがその機序は不詳である.本研究では一側尿管結紮(unilateral ureteral obstruction;UUO)マウスモデルを用いて,SEMA3Aと腎臓線維化の関連およびSEMA3A阻害剤の効果を検討した.UUOマウスの腎臓にはSEMA3Aおよびその受容体のNeuropilin-1(NRP1)発現が亢進しており,SEMA3A阻害剤によりUUOによる腎臓線維化は有意に軽減した.TGF-β1により誘導される培養ヒト尿細管上皮細胞の上皮間葉転換(epithelial-mesenchymal transition;EMT)はSEMA3A阻害剤により抑制された.JNK:c-Jun N-terminal kinase阻害剤(SP600125)はSEMA3Aにより誘導されるEMTを抑制したことから,JNKシグナルがSEMA3A経路による腎臓線維化に関与すると考えられた.さらに培養線維芽細胞にSEMA3Aを添付すると線維化マーカーの発現亢進が認められた.以上より腎臓線維化に対するSEMA3Aを制御する新たな治療戦略となりうることが示された.(著者抄録)

    researchmap

  • Co-occurrence of Three Systemic Diseases: ANCA-associated Vasculitis, Sjögren's syndrome and Sarcoidosis. Reviewed

    Kenji Tsuji, Yuka Okuyama, Yosuke Asano, Kimitomo Yamaoka, Shinji Kitamura, Jun Wada

    Internal medicine (Tokyo, Japan)   2022.11

     More details

    Authorship:Lead author, Corresponding author   Language:English   Publishing type:Research paper (scientific journal)  

    Anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV), Sjögren's syndrome (SjS), and sarcoidosis are systemic diseases targeting multiple organs. While a careful differential diagnosis of these diseases is often required, their co-occurrence in the same patient has been previously reported. We herein report a 58-year-old Japanese man diagnosed with the co-occurrence of three systemic diseases (AAV, SjS, and sarcoidosis) in addition to monoclonal gammopathy of undetermined significance (MGUS), which emphasizes the importance of considering the possible co-occurrence of these diseases as well as their differentiation.

    DOI: 10.2169/internalmedicine.0966-22

    PubMed

    researchmap

  • 人工知能を用いたテキストマイニングによる「血液透析」に関する医中誌Web収録原著論文および症例事例論文の考察 Reviewed

    喜多村 真治, 中納 弘幸, 森田 峻史, 高橋 謙作, 福島 和彦, 辻 憲二, 和田 淳

    日本透析医学会雑誌   55 ( 10 )   563 - 571   2022.10

     More details

    Language:Japanese   Publisher:(一社)日本透析医学会  

    医学論文数は2000年に入り急増し,増加に伴った情報氾濫が起きており,その適切な情報の取捨選択が重要である.今回われわれは医中誌Webに収蔵されている血液透析の原著論文および症例事例論文の要約をテキストマイニングし解析を行った.医学中央雑誌刊行会にて運営されている医中誌Webにて検索した,1979年以降に収載された「血液透析」の原著論文は26,408報であり,症例事例論文は8,936報であった.それらの原著論文の要旨・抄録を抽出した延べ単語総数は1,637,446語であり,症例事例論文は562,949語であった.原著論文解析では体外循環法や効率,生体適合性などの単語が頻出したのに対し,症例事例論文では実臨床の治療難渋例関連の単語の頻出が多く認められた.以上より医中誌Web収載の血液透析関連の原著論文および症例事例論文に対しテキストマイニングを用いて解析を行い,全論文から血液透析の実臨床の変遷を把握することが可能であった.(著者抄録)

    researchmap

  • The association between hypothyroidism and proteinuria in patients with chronic kidney disease: a cross-sectional study. Reviewed International journal

    Natsumi Matsuoka-Uchiyama, Kenji Tsuji, Yizhen Sang, Kensaku Takahashi, Kazuhiko Fukushima, Hidemi Takeuchi, Kenichi Inagaki, Haruhito A Uchida, Shinji Kitamura, Hitoshi Sugiyama, Jun Wada

    Scientific reports   12 ( 1 )   14999 - 14999   2022.9

     More details

    Authorship:Corresponding author   Language:English   Publishing type:Research paper (scientific journal)  

    Hypothyroidism is known to be correlated with kidney function and nephrotic range proteinuria. However, it is uncertain whether non-nephrotic proteinuria is associated with hypothyroidism. This study aimed to evaluate the association of proteinuria and hypothyroidism in chronic kidney disease (CKD) patients. We conducted a cross-sectional study composed of 421 CKD patients in a single hospital with measurements of 24-h urine protein excretion (UP) and thyroid function tests. Spearman correlation analysis revealed that 24-h Cr clearance (24hrCcr) was positively (r = 0.273, p < 0.001) and UP was negatively (r = - 0.207, p < 0.001) correlated with free triiodothyronine. Frequency distribution analysis stratified by CKD stage and UP for hypothyroidism revealed that the prevalence of hypothyroidism was higher among participants with higher CKD stage and nephrotic range proteinuria. Multivariate logistic regression analysis revealed that 24hrCcr and UP were significantly correlated with hypothyroidism (24hrCcr/10 mL/min decrease: odds ratio [OR], 1.29; 95% confidence interval [CI], 1.18-1.41; UP/1 g increase: OR, 1.10; 95% CI, 1.03-1.17). In addition, nephrotic range proteinuria, but not moderate UP (UP: 1.5-3.49 g/day), was significantly correlated with hypothyroidism compared to UP < 0.5 g/day. In summary, decreased kidney function and nephrotic range proteinuria, not non-nephrotic proteinuria, are independently associated with the hypothyroidism.

    DOI: 10.1038/s41598-022-19226-0

    PubMed

    researchmap

  • Simulation for ultrasound-guided renal biopsy using boiled egg. Reviewed International journal

    Kenji Tsuji, Shinji Kitamura, Haruhito A. Uchida, Jun Wada

    Nephrology (Carlton, Vic.)   27 ( 9 )   753 - 757   2022.6

     More details

    Authorship:Lead author, Corresponding author   Language:English   Publishing type:Research paper (scientific journal)  

    Real-time ultrasound-guided renal biopsy is generally applied to diagnose multiple kidney diseases. A practical simulation model is desired since it is an invasive technique with higher risks of complications such as bleeding. We developed a simple simulation tool for ultrasound-guided renal biopsy using boiled eggs. Boiled chicken eggs were embedded in the agar, and a biopsy simulation was performed using a real-time ultrasound-guided technique as the renal biopsy simulator by trainees and biopsy-proficient nephrologists, and the feedback from the participants was obtained. The ultrasonographic evaluation revealed a clear contrast between egg yolk and white, which clearly mimicked the kidney cortex and medulla region. In addition, we observed the needle entering the egg white under needle penetration, and we obtained the biopsy core consisting of egg white. As for the simulations, all the participants succeeded in obtaining the appropriate samples. A total of 92% of the trainees agreed that the simulation could reduce their fears of performing renal biopsies in patients. In addition, all the trainees and biopsy-proficient nephrologists recommend using the simulator for trainees before conducting renal biopsies on patients. The total cost of the simulator was low (<USD 1/simulator). Collectively, our simulation tool using boiled eggs may be a good candidate for practical simulation models of renal biopsy.

    DOI: 10.1111/nep.14079

    PubMed

    researchmap

  • 人工知能を用いたテキストマイニングによる「慢性腎臓病」に関する医学中央雑誌収録症例・事例論文の考察 Reviewed

    喜多村 真治, 辻 憲二, 高橋 謙作, 福島 和彦, 森田 峻史, 和田 淳

    腎と透析   92 ( 4 )   787 - 793   2022.4

     More details

    Language:Japanese   Publisher:(株)東京医学社  

    医学中央雑誌に収録された慢性腎臓病に関する症例・事例論文について、人工知能(AI)を用いてテキストマイニングと情報解析を行った。その結果、治療難渋例の報告が多いため透析に関する単語が多く、腎疾患名は糖尿病性腎症、慢性糸球体腎炎、腎硬化症が多かった。

    researchmap

  • Silica-associated systemic lupus erythematosus with lupus nephritis and lupus pneumonitis: A case report and a systematic review of the literature. Reviewed International journal

    Kazuhiko Fukushima, Haruhito A Uchida, Yasuko Fuchimoto, Tomoyo Mifune, Mayu Watanabe, Kenji Tsuji, Katsuyuki Tanabe, Masaru Kinomura, Shinji Kitamura, Yosuke Miyamoto, Sae Wada, Taisaku Koyanagi, Hitoshi Sugiyama, Takumi Kishimoto, Jun Wada

    Medicine   101 ( 7 )   e28872   2022.2

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    INTRODUCTION: Several epidemiological studies have shown that silica exposure triggers the onset of systemic lupus erythematosus (SLE); however, the clinical characteristics of silica-associated SLE have not been well studied. PATIENT CONCERNS: A 67-year-old man with silicosis visited a primary hospital because of a fever and cough. His respiratory condition worsened, regardless of antibiotic medication, and he was referred to our hospital. DIAGNOSIS: The patient showed leukopenia, lymphopenia, serum creatinine elevation with proteinuria and hematuria, decreased serum C3 level, and was positive for anti-double stranded DNA antibody, anti-nuclear antibody, and direct Coombs test. He was diagnosed with SLE. Renal biopsy was performed, and the patient was diagnosed with lupus nephritis (class IV-G(A/C) + V defined by the International Society of Nephrology/Renal Pathology Society classification). Computed tomography revealed acute interstitial pneumonitis, bronchoalveolar lavage fluid showed elevation of the lymphocyte fraction, and he was diagnosed with lupus pneumonitis. INTERVENTIONS: Prednisolone (50 mg/day) with intravenous cyclophosphamide (500 mg/body) were initiated. OUTCOMES: The patient showed a favorable response to these therapies. He was discharged from our hospital and received outpatient care with prednisolone slowly tapered off. He had cytomegalovirus and herpes zoster virus infections during treatment, which healed with antiviral therapy. REVIEW: We searched for the literature on sSLE, and selected 11 case reports and 2 population-based studies. The prevalence of SLE manifestations in sSLE patients were comparative to that of general SLE, particularly that of elderly-onset SLE. Our renal biopsy report and previous reports indicate that lupus nephritis of sSLE patients show as various histological patterns as those of general SLE patients. Among the twenty sSLE patients reported in the case articles, three patients developed lupus pneumonitis and two of them died of it. Moreover, two patients died of bacterial pneumonia, one developed aspergillus abscesses, one got pulmonary tuberculosis, and one developed lung cancer. CONCLUSION: Close attention is needed, particularly for respiratory system events and infectious diseases, when treating patients with silica-associated SLE using immunosuppressive therapies.

    DOI: 10.1097/MD.0000000000028872

    PubMed

    researchmap

  • Mesenchymal stem cells-derived extracellular vesicles as 'natural' drug delivery system for tissue regeneration Reviewed

    Kenji Tsuji, Shinji Kitamura, Jun Wada

    BIOCELL   46 ( 4 )   899 - 902   2022

     More details

    Authorship:Lead author   Language:English   Publishing type:Research paper (scientific journal)   Publisher:TECH SCIENCE PRESS  

    Mesenchymal stem cells (MSCs) have abilities to mediate tissue protection through mechanisms of antiapoptosis, anti-oxidative stress and anti-fibrosis as well as tissue regeneration through mechanisms of cell proliferation, differentiation and angiogenesis. These effects by MSCs are mediated by a variety of factors, including growth factors, cytokines and extracellular vesicles (EVs). Among these factors, EVs, containing proteins, mRNA and microRNAs (miRNA), may carry their contents into distant tissues with high stability. Therefore, the treatment with MSC-derived EVs may be promising as 'natural' drug delivery systems (DDS). Especially, the treatment of MSCderived EVs with the manipulation of specific miRNAs expression has been reported to be beneficial under a variety of diseases and tissue injuries. The overexpression of specific miRNAs in the EVs might be through pre-loading method using the gene editing system by plasmid vector or post-loading method to load miRNA mimics into EVs by electroporation or calcium chloride-mediated transfection. Despite current several challenges for clinical use, it should open the next era of regenerative medicine for a variety of diseases. In this article, we highlight the therapeutic potential of MSC-derived EVs as 'natural' DDS and current challenges.

    DOI: 10.32604/biocell.2022.018594

    Web of Science

    researchmap

  • The Association of Postprandial Triglyceride Variability with Renal Dysfunction and Microalbuminuria in Patients with Type 2 Diabetic Mellitus: A Retrospective and Observational Study. Reviewed International journal

    Natsumi Matsuoka-Uchiyama, Haruhito A Uchida, Shugo Okamoto, Yasuhiro Onishi, Katsuyoshi Katayama, Mariko Tsuchida-Nishiwaki, Hidemi Takeuchi, Rika Takemoto, Yoshiko Hada, Ryoko Umebayashi, Naoko Kurooka, Kenji Tsuji, Jun Eguchi, Hirofumi Nakajima, Kenichi Shikata, Jun Wada

    Journal of diabetes research   2022   3157841 - 3157841   2022

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    OBJECTIVE: We examined whether or not day-to-day variations in lipid profiles, especially triglyceride (TG) variability, were associated with the exacerbation of diabetic kidney disease. METHODS: We conducted a retrospective and observational study. First, 527 patients with type 2 diabetes mellitus (DM) who had had their estimated glomerular filtration rate (eGFR) checked every 6 months since 2012 for over 5 years were registered. Variability in postprandial TG was determined using the standard deviation (SD), SD adjusted (Adj-SD) for the number of measurements, and maximum minus minimum difference (MMD) during the first three years of follow-up. The endpoint was a ≥40% decline from baseline in the eGFR, initiation of dialysis or death. Next, 181 patients who had no micro- or macroalbuminuria in February 2013 were selected from among the 527 patients for an analysis. The endpoint was the incidence of microalbuminuria, initiation of dialysis, or death. RESULTS: Among the 527 participants, 110 reached a ≥40% decline from baseline in the eGFR or death. The renal survival was lower in the higher-SD, higher-Adj-SD, and higher-MMD groups than in the lower-SD, lower-Adj-SD, and lower-MMD groups, respectively (log-rank test p = 0.0073, 0.0059, and 0.0195, respectively). A lower SD, lower Adj-SD, and lower MMD were significantly associated with the renal survival in the adjusted model (hazard ratio, 1.62, 1.66, 1.59; 95% confidence intervals, 1.05-2.53, 1.08-2.58, 1.04-2.47, respectively). Next, among 181 participants, 108 developed microalbuminuria or death. The nonincidence of microalbuminuria was lower in the higher-SD, higher-Adj-SD, and higher-MMD groups than in the lower-SD, lower-Adj-SD, and lower-MMD groups, respectively (log-rank test p = 0.0241, 0.0352, and 0.0474, respectively). CONCLUSIONS: Postprandial TG variability is a novel risk factor for eGFR decline and the incidence of microalbuminuria in patients with type 2 DM.

    DOI: 10.1155/2022/3157841

    PubMed

    researchmap

  • Masked CKD in hyperthyroidism and reversible CKD status in hypothyroidism. Reviewed International journal

    Natsumi Uchiyama-Matsuoka, Kenji Tsuji, Haruhito A Uchida, Shinji Kitamura, Yoshihiko Itoh, Yuki Nishiyama, Eisaku Morimoto, Satoshi Fujisawa, Tomohiro Terasaka, Takayuki Hara, Kanako Ogura-Ochi, Kenichi Inagaki, Jun Wada

    Frontiers in endocrinology   13   1048863 - 1048863   2022

     More details

    Authorship:Corresponding author   Language:English   Publishing type:Research paper (scientific journal)  

    INTRODUCTION: While it is well known that thyroid function may affect kidney function, the transition of the chronic kidney disease (CKD) status before and after treatment for thyroid disorders, as well as the factors affecting this change, remains to be explored. In the present study, we focused on the change in kidney function and their affecting factors during the treatment for both hyperthyroidism and hypothyroidism. METHODS: Eighty-eight patients with hyperthyroidism and fifty-two patients with hypothyroidism were enrolled in a retrospective and longitudinal case series to analyze the changes in kidney function and their affecting factors after treatment for thyroid disorders. RESULTS: Along with the improvement of thyroid function after treatment, there was a significant decrease in estimated glomerular filtration rate (eGFR) in hyperthyroidism (an average ΔeGFR of -41.1 mL/min/1.73 m2) and an increase in eGFR in hypothyroidism (an average ΔeGFR of 7.1 mL/min/1.73 m2). The multiple linear regression analysis revealed that sex, eGFR, free thyroxine (FT4) and free triiodothyronine (FT3) could be considered independent explanatory variables for ΔeGFR in hyperthyroidism, while age, eGFR, and FT3 were detected as independent explanatory variables in hypothyroidism. In addition, the stratification by kidney function at two points, pre- and post-treatment for thyroid disorders, revealed that 4.5% of the participants with hyperthyroidism were pre-defined as non-CKD and post-defined as CKD, indicating the presence of "masked" CKD in hyperthyroidism. On the other hand, 13.5% of the participants with hypothyroidism presented pre-defined CKD and post-defined non-CKD, indicating the presence of "reversible" CKD status in hypothyroidism. CONCLUSIONS: We uncovered the population of masked CKD in hyperthyroidism and reversible CKD status in hypothyroidism, thereby re-emphasizing the importance of a follow-up to examine kidney function after treatment for hyperthyroidism and the routine evaluation of thyroid function in CKD patients as well as the appropriate hormone therapy if the patient has hypothyroidism.

    DOI: 10.3389/fendo.2022.1048863

    PubMed

    researchmap

  • Potential Strategies for Kidney Regeneration With Stem Cells: An Overview. Reviewed International journal

    Kenji Tsuji, Shinji Kitamura, Jun Wada

    Frontiers in cell and developmental biology   10   892356 - 892356   2022

     More details

    Authorship:Lead author   Language:English   Publishing type:Research paper (scientific journal)  

    Kidney diseases are a major health problem worldwide. Despite advances in drug therapies, they are only capable of slowing the progression of kidney diseases. Accordingly, potential kidney regeneration strategies with stem cells have begun to be explored. There are two different directions for regenerative strategies, de novo whole kidney fabrication with stem cells, and stem cell therapy. De novo whole kidney strategies include: 1) decellularized scaffold technology, 2) 3D bioprinting based on engineering technology, 3) kidney organoid fabrication, 4) blastocyst complementation with chimeric technology, and 5) the organogenic niche method. Meanwhile, stem cell therapy strategies include 1) injection of stem cells, including mesenchymal stem cells, nephron progenitor cells, adult kidney stem cells and multi-lineage differentiating stress enduring cells, and 2) injection of protective factors secreted from these stem cells, including growth factors, chemokines, and extracellular vesicles containing microRNAs, mRNAs and proteins. Over the past few decades, there have been remarkable step-by-step developments in these strategies. Here, we review the current advances in the potential strategies for kidney regeneration using stem cells, along with their challenges for possible clinical use in the future.

    DOI: 10.3389/fcell.2022.892356

    PubMed

    researchmap

  • Semaporin3A-inhibitor ameliorates renal fibrosis through the regulation of JNK signaling. Reviewed International journal

    Yizhen Sang, Kenji Tsuji, Kazuhiko Fukushima, Kensaku Takahashi, Shinji Kitamura, Jun Wada

    American journal of physiology. Renal physiology   321 ( 6 )   F740-F756   2021.11

     More details

    Authorship:Corresponding author   Language:English   Publishing type:Research paper (scientific journal)  

    Renal fibrosis is the common pathological pathway in progressive renal diseases. In the study, we analyzed the roles of Semaphorin 3A (SEMA3A) on renal fibrosis and the effect of SEMA3A-inhibitor (SEMA3A-I) using unilateral ureteral obstruction (UUO) mouse model. The expression of SEMA3A in the proximal tubulus and neuropilin-1 (NRP1), a recepor of SEMA3A, in fibloblast and tubular cells were increased in the UUO kidneys. The increased expression of myofibroblast marker tenascin-C and fibronection as well as renal fibrosis were increased in UUO kidneys, all of which were ameliorated by SEMA3A-I. In addition, c-Jun N-terminal kinase (JNK) signaling pathway known as the target of SEMA3A signaling, was activated in proximal tubular cells and fibroblast cells after UUO surgery while SEMA3A-I significantly attenuated the activation. In vitro, treatments with SEMA3A as well as transforming growth factor-β1 (TGF-β1) in human proximal tubular cells lost epithelial cell characters while SEMA3A-I significantly ameliorated this transformation. JNK inhibitor, SP600125, partially reversed SEMA3A and TGF-β1-induced cell transformation, indicating that JNK signaling is involved in SEMA3A-induced renal fibrosis. In addition, the treatment with SEMA3A in fibroblast cells activated the expression of tenascin-C, collagen type I and fibronection, indicating that SEMA3A may accelerate renal fibrosis through the activation of fibroblast cells. The analysis of human data revealed the positive correlation between urinary SEMA3A and urinary N-acetyl-β-D-glucosaminidase, indicating the association between SEMA3A and tubular injury. In conclusion, SEMA3A signaling is involved in renal fibrosis through JNK signaling pathway and SEMA3A-I might be the therapeutic option for protecting from renal fibrosis.

    DOI: 10.1152/ajprenal.00234.2021

    PubMed

    researchmap

  • 人工知能を用いたテキストマイニングによる「慢性腎臓病」に関する医学中央雑誌収録原著論文の考察 Reviewed

    喜多村 真治, 高橋 謙作, 福島 和彦, 辻 憲二, 森田 峻史, 和田 淳

    日本腎臓学会誌   63 ( 8 )   995 - 1006   2021.11

     More details

    Language:Japanese   Publisher:(一社)日本腎臓学会  

    医学の進歩は著しく,腎臓疾患の概念や診断・治療も大きく変化している。医学論文数は2000年に入り急増し,増加に伴った情報氾濫が起きており,その適切な情報の取捨選択は限られた時間の中では困難である。今回われわれは医学中央雑誌に収蔵されている腎臓領域の原著論文の要約を全てテキストマイニングし解析を行った。医学中央雑誌にて検索した1982年以降に収載された「慢性腎臓病」関連の論文数(症例報告・事例を除く)は12,801報であった。それらの原著論文の要約・アブストラクトから抽出した述べ単語総数は8,556,712語であった。「慢性腎臓病」で医学中央雑誌から論文を抽出しているにも関わらず,上位に挙がった単語には「透析」,「血液透析」などが「慢性腎臓病」,「慢性腎不全」よりも出現頻度は高かった。単語のネットワーク構造解析では,「透析」,「血圧」,「慢性腎臓病」,「透析条件」などのグループが認められ,トピックとして多くの論文があることが示唆された。単語頻度推移解析では年代ごとの出現単語頻度を解析したところ,「慢性腎臓病」や慢性腎臓病の機能を評価する「eGFR」は2005年以降に多く記載されており,「慢性腎不全」は1982年以降認められていたが,2002年以降には徐々にその割合は減少しており,慢性腎不全といった腎機能低下を示す包括的な単語使用から,慢性腎臓病の提唱により単語出現頻度が移行していることが示唆された。以上より「慢性腎臓病」関連論文では透析に関係する単語が多く抽出された。一方,各糸球体性疾患の病名は多岐にわたり,反対に末期腎不全の腎代替療法は血液透析や腹膜透析に集約されている可能性も示唆された。医学中央雑誌に収載されている慢性腎臓病関連の原著論文をテキストマイニングの手法を用いて解析を行い,慢性腎臓病関連の変動を把握することが可能であった。(著者抄録)

    researchmap

  • Kidney cyst infection through a fistula between bladder and retroperitoneal abscess in a polycystic kidney disease patient. Reviewed International journal

    Takato Nakadoi, Kenji Tsuji, Takehiro Iwata, Eriko Eto, Hisashi Masuyama, Koji Tomita, Takao Hiraki, Shinji Kitamura, Hitoshi Sugiyama, Jun Wada

    Nephrology (Carlton, Vic.)   27 ( 4 )   383 - 384   2021.8

     More details

    Authorship:Corresponding author   Language:English  

    DOI: 10.1111/nep.13966

    PubMed

    researchmap

  • The resolution of immunofluorescent pathological images affects diagnosis for not only artificial intelligence but also human Reviewed

    Kensaku Takahashi, Shinji Kitamura, Kazuhiko Fukushima, Yizhen Sang, Kenji Tsuji, Jun Wada

    Journal of Nephropathology   10 ( 3 )   2021

     More details

    Publishing type:Research paper (scientific journal)  

    Introduction: For human, the resolution of images is important for diagnosis. Many clinical applications of artificial intelligence have been studied, however there are few reports on the difference in diagnosis between humans and artificial intelligence on the point of the renal pathological image resolution. Objectives: We examined whether the resolution of renal pathological images affects diagnosis of artificial intelligence and human. Patients and Methods: From 885 renal biopsy patients, we collected renal IgA immunofluorescent pathological images that resolution is 4, 16, 32, 64, 128, 256 and 512 pixels for each patient, and divided into training data set and validation data set, and created optimum deep learning models for each resolution. To compare with artificial intelligence nephrologist also tried to diagnose by using the same validation data set images. Results: We inputted IgA immunofluorescent pathological images into each optimum model. Human could not identify specific staining site with four pixels images, however, each resolution optimum model showed high accuracy, average over 80%. The each accuarcy was observed higher depending on the resolution. The area under the curve (AUC) showed higher diagnosis ratio depending on the resolution, too. Nephrologist performed high diagnosis sensitivity depending on resolution images as same as artificial intelligence. However, nephrologists’ diagnosis observed large variations in specificity depending on resolution. These results suggested that the resolution might affect specificity for human not artificial intelligence Conclusion: The resolution of images might be important for not AI but human on the point of specificity.

    DOI: 10.34172/jnp.2021.26

    Scopus

    researchmap

  • Sodium-Glucose Cotransporter 2 Inhibitors Work as a "Regulator" of Autophagic Activity in Overnutrition Diseases. Reviewed International journal

    Kazuhiko Fukushima, Shinji Kitamura, Kenji Tsuji, Jun Wada

    Frontiers in pharmacology   12   761842 - 761842   2021

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    Several large clinical trials have shown renal and cardioprotective effects of sodium-glucose cotransporter 2 (SGLT2) inhibitors in diabetes patients, and the protective mechanisms need to be elucidated. There have been accumulating studies which report that SGLT2 inhibitors ameliorate autophagy deficiency of multiple organs. In overnutrition diseases, SGLT2 inhibitors affect the autophagy via various signaling pathways, including mammalian target of rapamycin (mTOR), sirtuin 1 (SIRT1), and hypoxia-inducible factor (HIF) pathways. Recently, it turned out that not only stagnation but also overactivation of autophagy causes cellular damages, indicating that therapeutic interventions which simply enhance or stagnate autophagy activity might be a "double-edged sword" in some situations. A small number of studies suggest that SGLT2 inhibitors not only activate but also suppress the autophagy flux depending on the situation, indicating that SGLT2 inhibitors can "regulate" autophagic activity and help achieve the appropriate autophagy flux in each organ. Considering the complicated control and bilateral characteristics of autophagy, the potential of SGLT2 inhibitors as the regulator of autophagic activity would be beneficial in the treatment of autophagy deficiency.

    DOI: 10.3389/fphar.2021.761842

    PubMed

    researchmap

  • MicroRNAs as Biomarkers for Nephrotic Syndrome. Reviewed International journal

    Kenji Tsuji, Shinji Kitamura, Jun Wada

    International journal of molecular sciences   22 ( 1 )   2020.12

     More details

    Authorship:Lead author   Language:English   Publishing type:Research paper (scientific journal)  

    Nephrotic syndrome represents the clinical situation characterized by presence of massive proteinuria and low serum protein caused by a variety of diseases, including minimal change nephrotic syndrome (MCNS), focal segmental glomerulosclerosis (FSGS) and membranous glomerulonephropathy. Differentiating between diagnoses requires invasive renal biopsies in general. Even with the biopsy, we encounter difficulties to differentiate MCNS and FSGS in some cases. There is no other better option currently available for the diagnosis other than renal biopsy. MicroRNAs (miRNAs) are no-coding RNAs of approximately 20 nucleotides in length, which regulate target genes in the post-transcriptional processes and have essential roles in many diseases. MiRNAs in serum and urine have been shown as non-invasive biomarkers in multiple diseases, including renal diseases. In this article, we summarize the current knowledge of miRNAs as the promising biomarkers for nephrotic syndrome.

    DOI: 10.3390/ijms22010088

    PubMed

    researchmap

  • Tubulointerstitial Nephritis Cases With IgM-Positive Plasma Cells. Reviewed International journal

    Natsumi Matsuoka-Uchiyama, Kenji Tsuji, Kazuhiko Fukushima, Shinji Kitamura, Haruhito A Uchida, Hitoshi Sugiyama, Naoki Takahashi, Masayuki Iwano, Jun Wada

    Kidney international reports   5 ( 9 )   1576 - 1580   2020.9

     More details

    Authorship:Corresponding author   Language:English  

    DOI: 10.1016/j.ekir.2020.06.010

    PubMed

    researchmap

  • Podocytopathy as 'stand-alone' involvement in systemic lupus erythematosus: a case report. Reviewed International journal

    Kenji Tsuji, Yoko Takatsu, Yu Katayama, Kazuhiko Fukushima, Shinji Kitamura, Hitoshi Sugiyama, Jun Wada

    Lupus   29 ( 9 )   1148 - 1150   2020.8

     More details

    Authorship:Lead author, Corresponding author   Language:English  

    DOI: 10.1177/0961203320935988

    PubMed

    researchmap

  • Tubulointerstitial Nephritis and Uveitis Caused by Sjögren Syndrome Without Dryness. Reviewed International journal

    Soichiro Sugitani, Kenji Tsuji, Toshio Yamanari, Yoichi Hasegawa, Kentaro Inoue, Yuka Sogabe, Yukari Nakano, Shinji Kitamura, Tsutomu Ishizu, Jun Wada

    Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases   2020.7

     More details

    Authorship:Corresponding author   Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1097/RHU.0000000000001505

    PubMed

    researchmap

  • Deep Learning Could Diagnose Diabetic Nephropathy with Renal Pathological Immunofluorescent Images. Reviewed International journal

    Shinji Kitamura, Kensaku Takahashi, Yizhen Sang, Kazuhiko Fukushima, Kenji Tsuji, Jun Wada

    Diagnostics (Basel, Switzerland)   10 ( 7 )   2020.7

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    Artificial Intelligence (AI) imaging diagnosis is developing, making enormous steps forward in medical fields. Regarding diabetic nephropathy (DN), medical doctors diagnose them with clinical course, clinical laboratory data and renal pathology, mainly evaluate with light microscopy images rather than immunofluorescent images because there are no characteristic findings in immunofluorescent images for DN diagnosis. Here, we examined the possibility of whether AI could diagnose DN from immunofluorescent images. We collected renal immunofluorescent images from 885 renal biopsy patients in our hospital, and we created a dataset that contains six types of immunofluorescent images of IgG, IgA, IgM, C3, C1q and Fibrinogen for each patient. Using the dataset, 39 programs worked without errors (Area under the curve (AUC): 0.93). Five programs diagnosed DN completely with immunofluorescent images (AUC: 1.00). By analyzing with Local interpretable model-agnostic explanations (Lime), the AI focused on the peripheral lesion of DN glomeruli. On the other hand, the nephrologist diagnostic ratio (AUC: 0.75833) was slightly inferior to AI diagnosis. These findings suggest that DN could be diagnosed only by immunofluorescent images by deep learning. AI could diagnose DN and identify classified unknown parts with the immunofluorescent images that nephrologists usually do not use for DN diagnosis.

    DOI: 10.3390/diagnostics10070466

    PubMed

    researchmap

  • Adult kidney stem/progenitor cells contribute to regeneration through the secretion of trophic factors. Reviewed International journal

    Kenji Tsuji, Shinji Kitamura, Yizhen Sang, Kazuhiko Fukushima, Jun Wada

    Stem cell research   46   101865 - 101865   2020.7

     More details

    Authorship:Lead author   Language:English   Publishing type:Research paper (scientific journal)  

    Adult kidney stem cells are known to have important roles in renal regeneration after acute kidney injury. Although trophic factors from tissue stem cells have been reported to promote the regeneration of other organs, there is limited number of evidence of this phenomenon in the kidneys. Here, we explored the effects of secreted factors from kidney stem cells. We intraperitoneally administered culture supernatant obtained from adult rat kidney stem/progenitor cells into rat kidney ischemia/reperfusion injury models, and the treatment significantly ameliorated renal tubulointerstitial injury, suppressed tubular cell apoptosis, diminished inflammation and promoted the proliferation of both residual renal cells and immature cells. In vitro, treatment with culture supernatant from kidney stem cells significantly promoted cell proliferation and suppressed cisplatin-induced cell apoptosis in both normal rat kidney cells and kidney stem cells. In addition, treatment with culture supernatant increased the expression of nestin in normal rat kidney cells, suggesting the dedifferentiation of tubular cells into stem-like cells. Analysis of the culture supernatant revealed that it contained a variety of growth factors. Taken together, the results suggest that these factors together lead to renal regeneration. In conclusion, adult kidney stem cells contribute to renal regeneration indirectly through the secretion of regenerative factors.

    DOI: 10.1016/j.scr.2020.101865

    PubMed

    researchmap

  • Semaphorin3A-Inhibitor Ameliorates Doxorubicin-Induced Podocyte Injury. Reviewed International journal

    Yizhen Sang, Kenji Tsuji, Akiko Inoue-Torii, Kazuhiko Fukushima, Shinji Kitamura, Jun Wada

    International journal of molecular sciences   21 ( 11 )   2020.6

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    Podocyte injury is an independent risk factor for the progression of renal diseases. Semaphorin3A (SEMA3A), expressed in podocytes and tubular cells in the mammalian adult kidneys, has been reported to regulate diverse biological functions and be associated with renal diseases. Here, we investigated pathological roles of SEMA3A signaling on podocyte injury using a doxorubicin (Dox)-induced mouse model and examined the therapeutic effect of SEMA3A-inhibitor (SEMA3A-I). We demonstrated that Dox caused massive albuminuria and podocyte apoptosis as well as an increase of SEMA3A expression in podocytes, all of which were ameliorated with SEMA3A-I treatment. In addition, c-Jun N-terminal kinase (JNK), known as a downstream of SEMA3A signaling, was activated in Dox-injected mouse podocytes while SEMA3A-I treatment partially blocked the activation. In vitro, SEMA3A-I protected against Dox-induced podocyte apoptosis and recombinant SEMA3A caused podocyte apoptosis with activation of JNK signaling. JNK inhibitor, SP600125, attenuated SEMA3A-induced podocyte apoptosis, indicating that the JNK pathway would be involved in SEMA3A-induced podocyte apoptosis. Furthermore, the analysis of human data revealed a positive correlation between levels of urinary SEMA3A and protein, suggesting that SEMA3A is associated with podocyte injury. In conclusion, SEMA3A has essential roles in podocyte injury and it would be the therapeutic target for protecting from podocyte injury.

    DOI: 10.3390/ijms21114099

    PubMed

    researchmap

  • Sodium Glucose Co-Transporter 2 Inhibitor Ameliorates Autophagic Flux Impairment on Renal Proximal Tubular Cells in Obesity Mice. Reviewed International journal

    Kazuhiko Fukushima, Shinji Kitamura, Kenji Tsuji, Yizhen Sang, Jun Wada

    International journal of molecular sciences   21 ( 11 )   2020.6

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    Obesity is supposed to cause renal injury via autophagy deficiency. Recently, sodium glucose co-transporter 2 inhibitors (SGLT2i) were reported to protect renal injury. However, the mechanisms of SGLT2i for renal protection are unclear. Here, we investigated the effect of SGLT2i for autophagy in renal proximal tubular cells (PTCs) on obesity mice. We fed C57BL/6J mice with a normal diet (ND) or high-fat and -sugar diet (HFSD) for nine weeks, then administered SGLT2i, empagliflozin, or control compound for one week. Each group contained N = 5. The urinary N-acetyl-beta-d-glucosaminidase level in the HFSD group significantly increased compared to ND group. The tubular damage was suppressed in the SGLT2i-HFSD group. In electron microscopic analysis, multi lamellar bodies that increased in autophagy deficiency were increased in PTCs in the HFSD group but significantly suppressed in the SGLT2i group. The autophagosomes of damaged mitochondria in PTCs in the HFSD group frequently appeared in the SGLT2i group. p62 accumulations in PTCs were significantly increased in HFSD group but significantly suppressed by SGLT2i. In addition, the mammalian target of rapamycin was activated in the HFSD group but significantly suppressed in SGLT2i group. These data suggest that SGLT2i has renal protective effects against obesity via improving autophagy flux impairment in PTCs on a HFSD.

    DOI: 10.3390/ijms21114054

    PubMed

    researchmap

  • Pembrolizumab-induced hypothyroidism caused reversible increased serum creatinine levels: a case report. Reviewed International journal

    Natsumi Matsuoka, Kenji Tsuji, Eiki Ichihara, Takayuki Hara, Kazuhiko Fukushima, Kishio Toma, Shinji Kitamura, Kenichi Inagaki, Hitoshi Sugiyama, Jun Wada

    BMC nephrology   21 ( 1 )   113 - 113   2020.3

     More details

    Authorship:Corresponding author   Language:English   Publishing type:Research paper (scientific journal)  

    BACKGROUND: The advent of immune checkpoint inhibitors (ICIs) has significantly improved the prognosis of patients with advanced malignancies. On the other hand, these drugs might cause immune-related adverse events (irAEs) including endocrinopathies and nephropathies. Thyroid dysfunction is one of the most common irAEs. For ICIs-induced nephropathies, most cases are due to tubulointerstitial nephritis, which might require steroid treatment. Here, we report a patient with non-small cell lung cancer treated with ICI who developed increased serum creatinine (s-Cr) levels due to ICIs-induced hypothyroidism. CASE PRESENTATION: A 57-year-old Asian man with refractory non-small cell lung cancer under ICIs therapy (pembrolizumab, an anti-programmed cell death-1 monoclonal antibody) developed increased s-Cr levels 5 months after the pembrolizumab initiation. His laboratory data, renal biopsy, and Gallium-67 scintigraphy findings denied pembrolizumab-induced tubulointerstitial nephritis. His renal function was correlated with thyroid function. Despite the increase of s-Cr levels, serum cystatin C levels were normal, which could be explained by the hypothyroidism. Levothyroxine treatment improved renal function as well as thyroid function. Then pembrolizumab was resumed, and both his thyroid and renal function remained normal level. Ultimately, we concluded that the increased s-Cr levels were caused by pembrolizumab-induced hypothyroidism. CONCLUSION: All clinicians involved in ICI treatment need to recognize the possible increase in s-Cr levels caused by ICIs-induced hypothyroidism, and we propose monitoring serum cystatin C levels to differentiate ICIs-induced hypothyroidism from tubulointerstitial nephritis before invasive renal biopsies or steroid treatment, which are recommended by the prescribing information for pembrolizumab, are performed.

    DOI: 10.1186/s12882-020-01775-z

    PubMed

    researchmap

  • Immunomodulatory and Regenerative Effects of Mesenchymal Stem Cell-Derived Extracellular Vesicles in Renal Diseases. Reviewed International journal

    Kenji Tsuji, Shinji Kitamura, Jun Wada

    International journal of molecular sciences   21 ( 3 )   2020.1

     More details

    Authorship:Lead author   Language:English   Publishing type:Research paper (scientific journal)  

    Mesenchymal stem cells (MSCs) have immunomodulatory and regenerative effects in many organs, including the kidney. Emerging evidence has shown that the trophic effects from MSCs are mainly mediated by the paracrine mechanism rather than the direct differentiation of MSCs into injured tissues. These secretomes from MSCs include cytokines, growth factors, chemokines and extracellular vesicles (EVs) containing microRNAs, mRNAs, and proteins. Many research studies have revealed that secretomes from MSCs have potential to ameliorate renal injury in renal disease models, including acute kidney injury and chronic kidney disease through a variety of mechanisms. These trophic mechanisms include immunomodulatory and regenerative effects. In addition, accumulating evidence has uncovered the specific factors and therapeutic mechanisms in MSC-derived EVs. In this article, we summarize the recent advances of immunomodulatory and regenerative effects of EVs from MSCs, especially focusing on the microRNAs.

    DOI: 10.3390/ijms21030756

    PubMed

    researchmap

  • Integrin-Linked Kinase Deficiency in Collecting Duct Principal Cell Promotes Necroptosis of Principal Cell and Contributes to Kidney Inflammation and Fibrosis. Reviewed International journal

    Ming Huang, Shuai Zhu, Huihui Huang, Jinzhao He, Kenji Tsuji, William W Jin, Dongping Xie, Onju Ham, Diane E Capen, Weining Lu, Teodor G Păunescu, Baoxue Yang, Hua A Jenny Lu

    Journal of the American Society of Nephrology : JASN   30 ( 11 )   2073 - 2090   2019.11

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    BACKGROUND: Necroptosis is a newly discovered cell death pathway that plays a critical role in AKI. The involvement of integrin-linked kinase (ILK) in necroptosis has not been studied. METHODS: We performed experiments in mice with an Ilk deletion in collecting duct (CD) principal cells (PCs), and cultured tubular epithelial cells treated with an ILK inhibitor or ILK siRNA knockdown. RESULTS: Ilk deletion in CD PCs resulted in acute tubular injury and early mortality in mice. Progressive interstitial fibrosis and inflammation associated with the activation of the canonical TGF-β signaling cascade were detected in the kidneys of the mice lacking ILK in the CD PCs. In contrast to the minimal apoptosis detected in the animals' injured CDs, widespread necroptosis was present in ILK-deficient PCs, characterized by cell swelling, deformed mitochondria, and rupture of plasma membrane. In addition, ILK deficiency resulted in increased expression and activation of necroptotic proteins MLKL and RIPK3, and membrane translocation of MLKL in CD PCs. ILK inhibition and siRNA knockdown reduced cell survival in cultured tubular cells, concomitant with increased membrane accumulation of MLKL and/or phospho-MLKL. Administration of a necroptosis inhibitor, necrostatin-1, blocked cell death in vitro and significantly attenuated inflammation, interstitial fibrosis, and renal failure in ILK-deficient mice. CONCLUSIONS: The study demonstrates the critical involvement of ILK in necroptosis through modulation of the RIPK3 and MLKL pathway and highlights the contribution of CD PC injury to the development of inflammation and interstitial fibrosis of the kidney.

    DOI: 10.1681/ASN.2018111162

    PubMed

    researchmap

  • Pathological cardiac remodeling occurs early in CKD mice from unilateral urinary obstruction, and is attenuated by Enalapril. Reviewed International journal

    Onju Ham, William Jin, Lei Lei, Hui Hui Huang, Kenji Tsuji, Ming Huang, Jason Roh, Anthony Rosenzweig, Hua A Jenny Lu

    Scientific reports   8 ( 1 )   16087 - 16087   2018.10

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    Cardiovascular disease constitutes the leading cause of mortality in patients with chronic kidney disease (CKD) and end-stage renal disease. Despite increasing recognition of a close interplay between kidney dysfunction and cardiovascular disease, termed cardiorenal syndrome (CRS), the underlying mechanisms of CRS remain poorly understood. Here we report the development of pathological cardiac hypertrophy and fibrosis in early stage non-uremic CKD. Moderate kidney failure was induced three weeks after unilateral urinary obstruction (UUO) in mice. We observed pathological cardiac hypertrophy and increased fibrosis in UUO-induced CKD (UUO/CKD) animals. Further analysis indicated that this cardiac fibrosis was associated with increased expression of transforming growth factor β (TGF-β) along with significant upregulation of Smad 2/3 signaling in the heart. Moreover early treatment of UUO/CKD animals with an angiotensin-converting-enzyme inhibitor (ACE I), Enalapril, significantly attenuated cardiac fibrosis. Enalapril antagonized activation of the TGF-β signaling pathway in the UUO/CKD heart. In summary our study demonstrates the presence of pathological cardiac hypertrophy and fibrosis in mice early in UUO-induced CKD, in association with early activation of the TGF-β/Smad signaling pathway. We also demonstrate the beneficial effect of ACE I in alleviating this early fibrogenic process in the heart in UUO/CKD animals.

    DOI: 10.1038/s41598-018-34216-x

    PubMed

    researchmap

  • Manganese promotes intracellular accumulation of AQP2 via modulating F-actin polymerization and reduces urinary concentration in mice. Reviewed International journal

    Lei Lei, Ming Huang, Limin Su, Dongping Xie, Fahmy A Mamuya, Onju Ham, Kenji Tsuji, Teodor G Păunescu, Baoxue Yang, Hua A Jenny Lu

    American journal of physiology. Renal physiology   314 ( 2 )   F306-F316 - F316   2018.2

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    Aquaporin-2 (AQP2) is a water channel protein expressed in principal cells (PCs) of the kidney collecting ducts (CDs) and plays a critical role in mediating water reabsorption and urine concentration. AQP2 undergoes both regulated trafficking mediated by vasopressin (VP) and constitutive recycling, which is independent of VP. For both pathways, actin cytoskeletal dynamics is a key determinant of AQP2 trafficking. We report here that manganese chloride (MnCl2) is a novel and potent regulator of AQP2 trafficking in cultured cells and in the kidney. MnCl2 treatment promoted internalization and intracellular accumulation of AQP2. The effect of MnCl2 on the intracellular accumulation of AQP2 was associated with activation of RhoA and actin polymerization without modification of AQP2 phosphorylation. Although the level of total and phosphorylated AQP2 did not change, MnCl2 treatment impeded VP-induced phosphorylation of AQP2 at its serine-256, -264, and -269 residues and dephosphorylation at serine 261. In addition, MnCl2 significantly promoted F-actin polymerization along with downregulation of RhoA activity and prevented VP-induced membrane accumulation of AQP2. Finally, MnCl2 treatment in mice resulted in significant polyuria and reduced urinary concentration, likely due to intracellular relocation of AQP2 in the PCs of kidney CDs. More importantly, the reduced urinary concentration caused by MnCl2 treatment in animals was not corrected by VP. In summary, our study identified a novel effect of MnCl2 on AQP2 trafficking through modifying RhoA activity and actin polymerization and uncovered its potent impact on water diuresis in vivo.

    DOI: 10.1152/ajprenal.00391.2017

    PubMed

    researchmap

  • Secretomes from Mesenchymal Stem Cells against Acute Kidney Injury: Possible Heterogeneity. Reviewed International journal

    Kenji Tsuji, Shinji Kitamura, Jun Wada

    Stem cells international   2018   8693137 - 8693137   2018

     More details

    Authorship:Lead author   Language:English   Publishing type:Research paper (scientific journal)  

    A kidney has the ability to regenerate itself after a variety of renal injuries. Mesenchymal stem cells (MSCs) have been shown to ameliorate tissue damages during renal injuries and diseases. The regenerations induced by MSCs are primarily mediated by the paracrine release of soluble factors and extracellular vesicles, including exosomes and microvesicles. Extracellular vesicles contain proteins, microRNAs, and mRNAs that are transferred into recipient cells to induce several repair signaling pathways. Over the past few decades, many studies identified trophic factors from MSCs, which attenuate renal injury in a variety of animal acute kidney injury models, including renal ischemia-reperfusion injury and drug-induced renal injury, using microarray and proteomic analysis. Nevertheless, these studies have revealed the heterogeneity of trophic factors from MSCs that depend on the cell origins and different stimuli including hypoxia, inflammatory stimuli, and aging. In this review article, we summarize the secretomes and regenerative mechanisms induced by MSCs and highlight the possible heterogeneity of trophic factors from different types of MSC and different circumstances for renal regeneration.

    DOI: 10.1155/2018/8693137

    PubMed

    researchmap

  • Deletion of β1-integrin in collecting duct principal cells leads to tubular injury and renal medullary fibrosis. Reviewed International journal

    Fahmy A Mamuya, Dongping Xie, Lei Lei, Ming Huang, Kenji Tsuji, Diane E Capen, BaoXue Yang, Ralph Weissleder, Teodor G Păunescu, Hua A Jenny Lu

    American journal of physiology. Renal physiology   313 ( 4 )   F1026-F1037 - F1037   2017.10

     More details

    Language:English   Publishing type:Research paper (scientific journal)   Publisher:AMER PHYSIOLOGICAL SOC  

    The renal collecting duct (CD) contains two major cell types, intercalated (ICs) and principal cells (PCs). A previous report showed that deletion of β1-integrin in the entire renal CD causes defective CD morphogenesis resulting in kidney dysfunction. However, subsequent deletion of β1-integrin specifically in ICs and PCs, respectively, did not cause any morphological defects in the CDs. The discrepancy between these studies prompts us to reinvestigate the role of β1-integrin in CD cells, specifically in the PCs. We conditionally deleted β1-integrin in mouse CD PCs using a specific aquaporin-2 (AQP2) promoter Cre-LoxP system. The resulting mutant mice, β-1f/fAQP2-Cre+, had lower body weight, failed to thrive, and died around 8-12 wk. Their CD tubules were dilated, and some of them contained cellular debris. Increased apoptosis and proliferation of PCs were observed in the dilated CDs. Trichrome staining and electron microscopy revealed the presence of peritubular and interstitial fibrosis that is associated with increased production of extracellular matrix proteins including collagen type IV and fibronectin, as detected by immunoblotting. Further analysis revealed a significantly increased expression of transforming growth factor-β (TGF-β)-induced protein, fibronectin, and TGF-β receptor-1 mRNAs and concomitantly increased phosphorylation of SMAD-2 that indicates the activation of the TGF-β signaling pathway. Therefore, our data reveal that normal expression of β1-integrin in PCs is a critical determinant of CD structural and functional integrity and further support the previously reported critical role of β1-integrin in the development and/or maintenance of the CD structure and function.

    DOI: 10.1152/ajprenal.00038.2017

    Web of Science

    PubMed

    researchmap

  • Ultrastructural Characterization of the Glomerulopathy in Alport Mice by Helium Ion Scanning Microscopy (HIM). Reviewed International journal

    Kenji Tsuji, Hani Suleiman, Jeffrey H Miner, James M Daley, Diane E Capen, Teodor G Păunescu, Hua A Jenny Lu

    Scientific reports   7 ( 1 )   11696 - 11696   2017.9

     More details

    Authorship:Lead author   Language:English   Publishing type:Research paper (scientific journal)   Publisher:NATURE PUBLISHING GROUP  

    The glomerulus exercises its filtration barrier function by establishing a complex filtration apparatus consisting of podocyte foot processes, glomerular basement membrane and endothelial cells. Disruption of any component of the glomerular filtration barrier leads to glomerular dysfunction, frequently manifested as proteinuria. Ultrastructural studies of the glomerulus by transmission electron microscopy (TEM) and conventional scanning electron microscopy (SEM) have been routinely used to identify and classify various glomerular diseases. Here we report the application of newly developed helium ion scanning microscopy (HIM) to examine the glomerulopathy in a Col4a3 mutant/Alport syndrome mouse model. Our study revealed unprecedented details of glomerular abnormalities in Col4a3 mutants including distorted podocyte cell bodies and disorganized primary processes. Strikingly, we observed abundant filamentous microprojections arising from podocyte cell bodies and processes, and presence of unique bridging processes that connect the primary processes and foot processes in Alport mice. Furthermore, we detected an altered glomerular endothelium with disrupted sub-endothelial integrity. More importantly, we were able to clearly visualize the complex, three-dimensional podocyte and endothelial interface by HIM. Our study demonstrates that HIM provides nanometer resolution to uncover and rediscover critical ultrastructural characteristics of the glomerulopathy in Col4a3 mutant mice.

    DOI: 10.1038/s41598-017-12064-5

    Web of Science

    PubMed

    researchmap

  • Ezrin directly interacts with AQP2 and promotes its endocytosis. Reviewed International journal

    Wei Li, William W Jin, Kenji Tsuji, Ying Chen, Naohiro Nomura, Limin Su, Naofumi Yui, Julian Arthur, Susanna Cotecchia, Teodor G Paunescu, Dennis Brown, Hua A J Lu

    Journal of cell science   130 ( 17 )   2914 - 2925   2017.9

     More details

    Language:English   Publishing type:Research paper (scientific journal)   Publisher:COMPANY OF BIOLOGISTS LTD  

    The water channel aquaporin-2 (AQP2) is a major regulator of water homeostasis in response to vasopressin (VP). Dynamic trafficking of AQP2 relies on its close interaction with trafficking machinery proteins and the actin cytoskeleton. Here, we report the identification of ezrin, an actin-binding protein from the ezrin/radixin/moesin (ERM) family as an AQP2-interacting protein. Ezrin was first detected in a co-immunoprecipitation (co-IP) complex using an anti-AQP2 antibody in a proteomic analysis. Immunofluorescence staining revealed the co-expression of ezrin and AQP2 in collecting duct principal cells, and VP treatment caused redistribution of both proteins to the apical membrane. The ezrin-AQP2 interaction was confirmed by co-IP experiments with an anti-ezrin antibody, and by pulldown assays using purified full-length and FERM domain-containing recombinant ezrin. By using purified recombinant proteins, we showed that ezrin directly interacts with AQP2 C-terminus through its N-terminal FERM domain. Knocking down ezrin expression with shRNA resulted in increased membrane accumulation of AQP2 and reduced AQP2 endocytosis. Therefore, through direct interaction with AQP2, ezrin facilitates AQP2 endocytosis, thus linking the dynamic actin cytoskeleton network with AQP2 trafficking.

    DOI: 10.1242/jcs.204842

    Web of Science

    PubMed

    researchmap

  • Re-characterization of the Glomerulopathy in CD2AP Deficient Mice by High-Resolution Helium Ion Scanning Microscopy. Reviewed International journal

    Kenji Tsuji, Teodor G Păunescu, Hani Suleiman, Dongping Xie, Fahmy A Mamuya, Jeffrey H Miner, Hua A Jenny Lu

    Scientific reports   7 ( 1 )   8321 - 8321   2017.8

     More details

    Authorship:Lead author   Language:English   Publishing type:Research paper (scientific journal)   Publisher:NATURE PUBLISHING GROUP  

    Helium ion scanning microscopy (HIM) is a novel technology that directly visualizes the cell surface ultrastructure without surface coating. Despite its very high resolution, it has not been applied extensively to study biological or pathology samples. Here we report the application of this powerful technology to examine the three-dimensional ultrastructural characteristics of proteinuric glomerulopathy in mice with CD2-associated protein (CD2AP) deficiency. HIM revealed the serial alteration of glomerular features including effacement and disorganization of the slit diaphragm, followed by foot process disappearance, flattening and fusion of major processes, and eventual transformation into a podocyte sheet as the disease progressed. The number and size of the filtration slit pores decreased. Strikingly, numerous "bleb" shaped microprojections were observed extending from podocyte processes and cell body, indicating significant membrane dynamics accompanying CD2AP deficiency. Visualizing the glomerular endothelium and podocyte-endothelium interface revealed the presence of endothelial damage, and disrupted podocyte and endothelial integrity in 6 week-old Cd2ap-KO mice. We used the HIM technology to investigate at nanometer scale resolution the ultrastructural alterations of the glomerular filtration apparatus in mice lacking the critical slit diaphragm-associated protein CD2AP, highlighting the great potential of HIM to provide new insights into the biology and (patho)physiology of glomerular diseases.

    DOI: 10.1038/s41598-017-08304-3

    Web of Science

    PubMed

    researchmap

  • The level of urinary semaphorin3A is associated with disease activity in patients with minimal change nephrotic syndrome. Reviewed International journal

    Akiko Inoue-Torii, Shinji Kitamura, Jun Wada, Kenji Tsuji, Hirofumi Makino

    International journal of nephrology and renovascular disease   10   167 - 174   2017

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    Semaphorin3A is a secreted protein known to be involved in organogenesis, immune responses and cancer. In the kidney, semaphorin3A is expressed in the glomerular podocytes, distal tubules and collecting tubules, and believed to play a role in the regulation of the kidney development and function. We examined the serum and urinary semaphorin3A levels in 72 patients with renal disease and 5 healthy volunteers. The patients had been diagnosed with thin basement membrane disease (n=4), minimal change nephrotic syndrome (MCNS; n=22), IgA nephritis (n=21), membranous nephropathy (n=16) and focal segmental glomerular sclerosis (n=9). The level of urinary semaphorin3A in MCNS patients tended to be relatively high among all disease groups. We also investigated the urinary semaphorin3A level in 7 patients with MCNS from disease onset to remission during the drug therapy. MCNS patients in pre-remission states had higher urinary semaphorin3A levels than those in post-remission states receiving immunosuppressive therapies. These results suggested that the urinary semaphorin3A level correlates with the MCNS activity. Semaphorin3A has the potential as a biomarker for MCNS to clarify the reactivity for therapy and may be useful in examining other glomerular diseases with proteinuria as well.

    DOI: 10.2147/IJNRD.S132980

    PubMed

    researchmap

  • Trophic Factors from Tissue Stem Cells for Renal Regeneration. Reviewed International journal

    Kenji Tsuji, Shinji Kitamura

    Stem cells international   2015   537204 - 537204   2015

     More details

    Authorship:Lead author   Language:English   Publishing type:Research paper (scientific journal)  

    Stem cell therapies against renal injury have been advancing. The many trials for renal regeneration are reported to be effective in many kinds of renal injury models. Regarding the therapeutic mechanism, it is believed that stem cells contribute to make regeneration via not only direct stem cell differentiation in the injured space but also indirect effect via secreted factors from stem cells. Direct differentiation from stem cells to renal composed cells has been reported. They differentiate to renal composed cells and make functions. However, regarding renal regeneration, stem cells are discussed to secrete many kinds of growth factors, cytokines, and chemokines in paracrine or autocrine manner, which protect against renal injury, too. In addition, it is reported that stem cells have the ability to communicate with nearby cells via microvesicle-related RNA and proteins. Taken together from many reports, many secreted factors from stem cells were needed for renal regeneration orchestrally with harmony. In this review, we focused on the effects and insights of stem cells and regenerative factors from stem cells.

    DOI: 10.1155/2015/537204

    PubMed

    researchmap

  • Hypoxia-inducible factor 1α regulates branching morphogenesis during kidney development. Reviewed International journal

    Kenji Tsuji, Shinji Kitamura, Hirofumi Makino

    Biochemical and biophysical research communications   447 ( 1 )   108 - 14   2014.4

     More details

    Authorship:Lead author   Language:English   Publishing type:Research paper (scientific journal)   Publisher:ACADEMIC PRESS INC ELSEVIER SCIENCE  

    The kidneys are exposed to hypoxic conditions during development. Hypoxia-inducible factor (HIF), an important mediator of the response to hypoxia, is believed to have an important role in development. However, the relationship between HIF and branching morphogenesis has not been elucidated clearly. In this study, we examined whether HIF regulates kidney development. We harvested kidneys from day 13 rat embryos (E13Ks) and cultured the organs under normoxic (20% O2/5% CO2) or hypoxic (5% O2/5% CO2) conditions. We evaluated the kidneys based on morphology and gene expression. E13Ks cultured under hypoxic conditions had significantly more ureteric bud (UB) branching than the E13Ks cultured under normoxic conditions. In addition, the mRNA levels of GDNF and GDNF receptor (GFR-α1), increased under hypoxic conditions in E13Ks. When we cultured E13Ks with the HIF-1α inhibitor digoxin or with siRNA targeting HIF-1α under hypoxic conditions, we did not observe increased UB branching. In addition, the expression of GDNF and GFR-α1 was inhibited under hypoxic conditions when the kidneys were treated with siRNA targeting HIF-1α. We also elucidated that hypoxia inhibited UB cell apoptosis and promoted the expression of FGF7 mRNA levels in metanephric mesenchymal (MM) cells in vitro. These findings suggest that hypoxic condition has important roles in inducing branching morphogenesis during kidney development. Hypoxia might mediate branching morphogenesis via not only GDNF/Ret but also FGF signaling pathway.

    DOI: 10.1016/j.bbrc.2014.03.111

    Web of Science

    PubMed

    researchmap

  • The selection of peritoneal mesothelial cells is important for cell therapy to prevent peritoneal fibrosis. Reviewed International journal

    Shinji Kitamura, Naoya Horimoto, Kenji Tsuji, Akiko Inoue, Keiichi Takiue, Hitoshi Sugiyama, Hirofumi Makino

    Tissue engineering. Part A   20 ( 3-4 )   529 - 39   2014.2

     More details

    Language:English   Publishing type:Research paper (scientific journal)   Publisher:MARY ANN LIEBERT, INC  

    Long-term peritoneal dialysis (PD) causes chronic peritoneal damage. Peritoneal mesothelial cells (PMCs) play an important role in peritoneal function. We investigated the possibility of cell therapy using the PMCs to prevent peritoneal damage in PD patients. We harvested human PMCs from the PD effluent of PD patients. The PMCs were separated based on morphological characteristics into epithelial-like (Epi) cells and fibroblast-like (Fib) cells by the limiting dilution method. We transplanted these cells into nude mice whose parietal and visceral peritoneum were scratched by mechanical scraping. The transplanted cells were detected at the parietal and visceral peritoneum. Compared with the positive control, the Epi cell therapy group showed very few adhesions and exhibited no thickening of the parietal and visceral peritoneum. However, the group with Fib cell therapy could not inhibit peritoneal adhesion and thickening. In addition, hepatocyte growth factor was expressed by the grafted Epi cells but not Fib cells. Fib cells expressed vascular endothelial growth factor stronger than Epi cells. These two types of cells from the same patient showed different characteristics and effects for cell therapy. These findings suggest that the PMCs from the PD patient showed different characteristics, such as Epi cells and Fib cells, and the selection of PMCs is important for cell therapy on the point of not only the direct cellular interactions but also cytokine secretion from the grafted cells. Furthermore, the differences in the morphological cell characteristics may influence their role in peritoneal regeneration.

    DOI: 10.1089/ten.TEA.2013.0130

    Web of Science

    PubMed

    researchmap

  • Mizoribine inhibits the proliferation of renal stem/progenitor cells by G1/S arrest during renal regeneration. Reviewed

    Naoya Horimoto, Shinji Kitamura, Kenji Tsuji, Hirofumi Makino

    Acta medica Okayama   68 ( 1 )   7 - 15   2014

     More details

    Language:English   Publishing type:Research paper (scientific journal)   Publisher:OKAYAMA UNIV MED SCHOOL  

    Immunosuppressive agents are generally administered to treat kidney diseases. However, it is unclear whether renal stem/progenitor cells are directly affected by the immunosuppressive agents. We used normal rat kidney cells, ureteric bud cells and rat kidney stem/progenitor cells in this study. Mizoribine (MZR), cyclophosphamide (CPA) and cyclosporine (CyA) were added to the culture media of these cells. We evaluated the effects of these immunosuppressive agents on cell proliferation using an electrical cell-substrate impedance sensing system (ECIS) and their effects on the process of renal regeneration using the ischemia-reperfusion (I/R) injury rat model. The ECIS data showed that proliferation of each of the 3 types of cells was significantly suppressed by MZR. MZR treatment enhanced renal tubular injury in ischemia-reperfusion (I/R) injured rats, and significantly decreased levels of M-phase cells and Nestin-positive cells. These results suggested that MZR inhibits the cell cycle of renal stem/progenitor cells;thus, physicians should take note that MZR might affect not only inflammation but also renal regeneration.

    DOI: 10.18926/AMO/52138

    Web of Science

    PubMed

    researchmap

  • Membranous nephropathy with acquired factor V inhibitor: a case report. Reviewed International journal

    Shinji Kitamura, Mahito Misawa, Sayaka Namba, Kenji Tsuji, Rikako Torigoe, Midori Shima, Hirofumi Makino

    BMC research notes   6   553 - 553   2013.12

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    BACKGROUND: Membranous nephropathy is one of the most common causes of nephrotic syndrome in adults. In contrast, acquired factor V inhibitor is a rare bleeding disorder. CASE PRESENTATION: A 62-year-old Asian man with a history of cerebral hemorrhage, purpura, eosinophilia and hyper immunoglobulin E syndrome developed proteinuria. The bleeding disorder was diagnosed with acquired factor V inhibitors. A renal biopsy revealed that he suffered from membranous nephropathy with glomerular endothelial damage which is reported to be involved in another factor disorder. After the steroid administration, the coagulation test and proteinuria were improved. CONCLUSIONS: The presence of factor V inhibitors may have been involved in the development of membranous nephropathy.

    DOI: 10.1186/1756-0500-6-553

    PubMed

    researchmap

  • A case of focal segmental glomerulosclerosis in an adult patient with hypogammaglobulinemia superimposed on membranoproliferative glomerulonephritis in childhood. Reviewed International journal

    Kenji Tsuji, Haruhito Adam Uchida, Tetsuichirou Ono, Tatsuyuki Inoue, Katsuji Shinagawa, Shinji Kitamura, Yohei Maeshima, Hitoshi Sugiyama, Hirofumi Makino

    BMC nephrology   13   46 - 46   2012.6

     More details

    Authorship:Lead author   Language:English   Publishing type:Research paper (scientific journal)  

    BACKGROUND: Common variable immunodeficiency (CVID) is a disorder characterized by hypogammaglobulinemia without a known predisposing cause. CASE PRESENTATION: We report a 36-year-old man who had suffered membranoproliferative glomerulonephritis (MPGN) in his childhood, later diagnosed with CVID at 35 years of age. He presented at our hospital with signs of proteinuria. A renal biopsy revealed he suffered from focal segmental glomerulosclerosis (FSGS), possibly due to obesity and hypertension, not CVID - associated MPGN. CONCLUSION: This is the first case report of FSGS in a CVID patient. In this case, we have to pay attention not only to the treatment of obesity and hypertension for FSGS but also to the recurrence of immune-complex glomerulonephritis such as MPGN, in case of the restoration of hypogammaglobulinemia.

    DOI: 10.1186/1471-2369-13-46

    PubMed

    researchmap

▼display all

Books

  • 【SGLT2阻害薬から見えてくる新たな生体システムの姿】SGLT2阻害剤のオートファジー制御による臓器保護作用

    辻憲二, 福島和彦, 喜多村真治, 和田淳

    細胞 55(4)  2023.4 

     More details

  • セマフォリン3A経路と糸球体上皮細胞障害

    辻憲二, 喜多村真治( Role: Contributor ,  研究者の最新動向)

    Precision Medicine  2022.8 

     More details

  • 人工知能を用いたテキストマイニングによる「慢性腎臓病」に関する医学中央雑誌収録症例・事例論文の考察

    喜多村真治, 辻憲二, 高橋謙作, 福島和彦, 森田峻史, 和田淳

    腎と透析  2022.4 

     More details

  • セマフォリン3A経路を介した糸球体上皮細胞障害機序の解明

    辻憲二, 喜多村真治( Role: Contributor ,  最先端医療の今)

    Medical Science Digest  2022.2 

     More details

  • 「総合診療」2020年6月号

    ( Role: Contributor ,  血液透析療法をしない場合の症状への対応~浮腫、食思不振等)

    医学書院  2020.6 

     More details

  • 「総合診療」2020年6月号

    ( Role: Contributor ,  薬物療法のコツ~降圧薬と利尿薬、高カリウム血症改善薬等の使い方)

    医学書院  2020.6 

     More details

  • 糖尿病×CKD診療ガイド Q&A 2012

    ( Role: Contributor ,  26項:高尿酸血症とは)

    南山堂  2012 

     More details

▼display all

MISC

  • 若手によるホットな臨床研究の祭典 人工知能による自然言語処理からの医学研究の方向性

    辻 憲二, 喜多村 真治, 和田 淳

    日本腎臓学会誌   65 ( 6-W )   749 - 749   2023.9

     More details

    Language:Japanese   Publisher:(一社)日本腎臓学会  

    researchmap

  • AKI研究の最先端 急性腎障害の診断と治療におけるmicroRNAの有用性

    辻 憲二, 喜多村 真治, 和田 淳

    日本腎臓学会誌   65 ( 3 )   226 - 226   2023.5

     More details

    Language:Japanese   Publisher:(一社)日本腎臓学会  

    researchmap

  • スチレン系軟質樹脂を用いた腎生検シミュレーターの開発と有用性の検討

    辻 憲二, 喜多村 真治, 和田 淳

    日本腎臓学会誌   65 ( 3 )   326 - 326   2023.5

     More details

    Language:Japanese   Publisher:(一社)日本腎臓学会  

    researchmap

  • 岡山市CKDネットワーク(OCKD-NET)におけるCKD病診連携12年後の追跡調査

    大西 康博, 内田 治仁, 田中 景子, 岡本 修吾, 竹内 英実, 辻 憲二, 田邊 克幸, 森永 裕士, 喜多村 真治, 前島 洋平, 太田 康介, 丸山 啓輔, 大城 義之, 森岡 茂, 瀧上 慶一, 蒲生 直幸, 杉山 斉, 和田 淳

    日本腎臓学会誌   65 ( 3 )   240 - 240   2023.5

     More details

    Language:Japanese   Publisher:(一社)日本腎臓学会  

    researchmap

  • 岡山市CKDネットワーク(OCKD-NET)2の登録時データ解析 OCKD-NET1との比較

    田中 景子, 内田 治仁, 大西 康博, 岡本 修吾, 竹内 英実, 辻 憲二, 田邊 克幸, 森永 裕士, 太田 康介, 丸山 啓輔, 大城 義之, 森岡 茂, 瀧上 慶一, 蒲生 直幸, 杉山 斉, 和田 淳

    日本腎臓学会誌   65 ( 3 )   268 - 268   2023.5

     More details

    Language:Japanese   Publisher:(一社)日本腎臓学会  

    researchmap

  • 医学生に対する腎セミナー開催についての検討

    辻 憲二, 岡本 修吾, 大西 康博, 田中 景子, 竹内 英実, 田邊 克幸, 森永 裕士, 内田 治仁, 喜多村 真治, 和田 淳

    日本腎臓学会誌   65 ( 3 )   326 - 326   2023.5

     More details

    Language:Japanese   Publisher:(一社)日本腎臓学会  

    researchmap

  • 【SGLT2阻害薬から見えてくる新たな生体システムの姿】SGLT2阻害剤のオートファジー制御による臓器保護作用

    辻 憲二, 福島 和彦, 喜多村 真治, 和田 淳

    細胞   55 ( 4 )   205 - 208   2023.4

     More details

    Language:Japanese   Publisher:(株)ニュー・サイエンス社  

    Sodium-glucose cotransporter 2(SGLT2)阻害剤の腎臓および心臓保護効果は複数の大規模な臨床試験の結果から明らかになっている。SGLT2阻害剤による臓器保護効果の機序は解明されていない点が多いが,その機序の一つにオートファジー不全の改善効果があることが分かってきた。SGLT2阻害剤は尿中へのグルコース排泄による絶食様状態を介してオートファジーの制御に重要であるシグナル伝達経路のmTOR,AMP活性化プロテインキナーゼ(AMPK),サーチュイン1(SIRT1),低酸素誘導因子(HIF)の制御を介してオートファジーフラックスを増強すると考えられる。特に腎臓では近位尿細管細胞と糸球体上皮細胞(ポドサイト),心臓では心筋細胞のオートファジー制御を介して保護効果がもたらされる。本稿ではSGLT2阻害剤のオートファジー制御による臓器保護作用についての知見を概観する。(著者抄録)

    researchmap

  • 造血幹細胞移植後肺障害に対する肺移植後の急性拒絶反応で重症化した患者に栄養的アプローチを行った一症例

    三村 智美, 深川 真里, 片山 祥子, 高橋 絢子, 寺本 賀一, 金 聖暎, 田邉 浩代, 大木 晴美, 大森 裕子, 園井 教裕, 山本 昌直, 辻 憲二, 菊地 覚次, 四方 賢一

    日本病態栄養学会誌   26 ( Suppl. )   S - 74   2023.1

     More details

    Language:Japanese   Publisher:(一社)日本病態栄養学会  

    researchmap

  • 研究者の最新動向 セマフォリン3A経路と糸球体上皮細胞障害

    辻 憲二, 喜多村 真治

    Precision Medicine   5 ( 8 )   759 - 762   2022.8

     More details

    Language:Japanese   Publisher:(株)北隆館  

    腎糸球体障害の進行課程における共通経路として糸球体上皮細胞(ポドサイト)障害が重要であるが、その病態機序は十分に解明されていない。セマフォリン3A(SEMA3A)は細胞間の情報伝達物質として機能する分泌型蛋白で、細胞増殖、遊走、免疫細胞の制御などの多彩な生理活性作用を持つ。筆者らはポドサイト障害マウスモデルにおいて、ポドサイト内のSEMA3A経路の活性化とその下流のc-Jun N-terminal Kinase(JNK)シグナルを介してアポトーシスが誘導されること、さらにその障害はSEMA3A阻害剤により抑制されることを解明し、ポドサイト障害に対するSEMA3Aをターゲットとする新たな治療法の可能性を示した。(著者抄録)

    researchmap

  • ゆで卵を用いた模擬腎生検 コロンブスの卵

    辻 憲二, 田中 景子, 竹内 英実, 田邊 克幸, 森永 裕士, 木野村 賢, 内田 治仁, 喜多村 真治, 杉山 斉, 和田 淳

    日本腎臓学会誌   64 ( 3 )   297 - 297   2022.5

     More details

    Language:Japanese   Publisher:(一社)日本腎臓学会  

    researchmap

  • 岡山市CKDネットワーク(OCKD-NET)におけるCKD病診連携11年後の追跡調査

    大西 康博, 内田 治仁, 竹内 英実, 田中 景子, 辻 憲二, 田邊 克幸, 森永 裕士, 木野村 賢, 喜多村 真治, 前島 洋平, 杉山 斉, 太田 康介, 丸山 啓輔, 大城 義之, 森岡 茂, 瀧上 慶一, 蒲生 直幸, 和田 淳

    日本腎臓学会誌   64 ( 3 )   234 - 234   2022.5

     More details

    Language:Japanese   Publisher:(一社)日本腎臓学会  

    researchmap

  • 腎生検標本における腎のVeno-muscular Complex Variantの予後的価値 観察的コホート研究(The Prognostic Value of Renal Veno-muscular Complex Variant in Native Kidney Biopsy Specimens: An observational cohort study)

    Tsuji Kenji, Takahashi Kensaku, Morita Takafumi, Onishi Yasuhiro, Kitamura Shinji, Sugiyama Hitoshi, Wada Jun

    日本腎臓学会誌   64 ( 3 )   309 - 309   2022.5

     More details

    Language:English   Publisher:(一社)日本腎臓学会  

    researchmap

  • ゆで卵を用いた模擬腎生検 コロンブスの卵

    辻 憲二, 田中 景子, 竹内 英実, 田邊 克幸, 森永 裕士, 木野村 賢, 内田 治仁, 喜多村 真治, 杉山 斉, 和田 淳

    日本腎臓学会誌   64 ( 3 )   297 - 297   2022.5

     More details

    Language:Japanese   Publisher:(一社)日本腎臓学会  

    researchmap

  • 岡山市CKDネットワーク(OCKD-NET)におけるCKD病診連携11年後の追跡調査

    大西 康博, 内田 治仁, 竹内 英実, 田中 景子, 辻 憲二, 田邊 克幸, 森永 裕士, 木野村 賢, 喜多村 真治, 前島 洋平, 杉山 斉, 太田 康介, 丸山 啓輔, 大城 義之, 森岡 茂, 瀧上 慶一, 蒲生 直幸, 和田 淳

    日本腎臓学会誌   64 ( 3 )   234 - 234   2022.5

     More details

    Language:Japanese   Publisher:(一社)日本腎臓学会  

    researchmap

  • 最先端医療の今 セマフォリン3A経路を介した糸球体上皮細胞障害機序の解明

    辻 憲二, 喜多村 真治

    Medical Science Digest   48 ( 2 )   92 - 93   2022.2

     More details

    Language:Japanese   Publisher:(株)ニュー・サイエンス社  

    腎糸球体障害の進行課程における共通経路として糸球体上皮細胞(ポドサイト)障害が重要であるが、ポドサイト障害に対する直接的な治療法は確立していない。セマフォリン3A(SEMA3A)は細胞間の情報伝達物質として機能する分泌型蛋白であり、細胞増殖、遊走、血管新生、免疫細胞の制御など多彩な生理活性作用を持つ。SEMA3Aはポドサイトに発現するが、その発現量増加と腎臓病進展との関連性が報告されている。筆者らは薬剤性ポドサイト障害モデルのポドサイトにおいて、SEMA3A経路の活性化とその下流のc-Jun N-terminal Kinase(JNK)シグナルを介してアポトーシスが誘導されること、さらにそれがSEMA3A阻害剤により抑制されることを解明し、ポドサイト障害に対するSEMA3Aをターゲットとする新たな治療法の可能性を示した。(著者抄録)

    researchmap

  • 人工知能を用いたテキストマイニングによる「慢性腎臓病」に関する医学中央雑誌収録原著論文の考察

    喜多村 真治, 高橋 謙作, 福島 和彦, 辻 憲二, 森田 峻史, 和田 淳

    日本腎臓学会誌   63 ( 8 )   995 - 1006   2021.11

     More details

    Language:Japanese   Publisher:(一社)日本腎臓学会  

    医学の進歩は著しく,腎臓疾患の概念や診断・治療も大きく変化している。医学論文数は2000年に入り急増し,増加に伴った情報氾濫が起きており,その適切な情報の取捨選択は限られた時間の中では困難である。今回われわれは医学中央雑誌に収蔵されている腎臓領域の原著論文の要約を全てテキストマイニングし解析を行った。医学中央雑誌にて検索した1982年以降に収載された「慢性腎臓病」関連の論文数(症例報告・事例を除く)は12,801報であった。それらの原著論文の要約・アブストラクトから抽出した述べ単語総数は8,556,712語であった。「慢性腎臓病」で医学中央雑誌から論文を抽出しているにも関わらず,上位に挙がった単語には「透析」,「血液透析」などが「慢性腎臓病」,「慢性腎不全」よりも出現頻度は高かった。単語のネットワーク構造解析では,「透析」,「血圧」,「慢性腎臓病」,「透析条件」などのグループが認められ,トピックとして多くの論文があることが示唆された。単語頻度推移解析では年代ごとの出現単語頻度を解析したところ,「慢性腎臓病」や慢性腎臓病の機能を評価する「eGFR」は2005年以降に多く記載されており,「慢性腎不全」は1982年以降認められていたが,2002年以降には徐々にその割合は減少しており,慢性腎不全といった腎機能低下を示す包括的な単語使用から,慢性腎臓病の提唱により単語出現頻度が移行していることが示唆された。以上より「慢性腎臓病」関連論文では透析に関係する単語が多く抽出された。一方,各糸球体性疾患の病名は多岐にわたり,反対に末期腎不全の腎代替療法は血液透析や腹膜透析に集約されている可能性も示唆された。医学中央雑誌に収載されている慢性腎臓病関連の原著論文をテキストマイニングの手法を用いて解析を行い,慢性腎臓病関連の変動を把握することが可能であった。(著者抄録)

    researchmap

  • 人工知能による症例報告のテキストマイニングの検討

    喜多村 真治, 辻 憲二, 福島 和彦, 高橋 謙作, 桑 藝禎, 和田 淳

    日本腎臓学会誌   63 ( 4 )   470 - 470   2021.6

     More details

    Language:Japanese   Publisher:(一社)日本腎臓学会  

    researchmap

  • 慢性腎臓病における貧血管理 Kakusyo 3C Studyからの検討

    奥山 由加, 内田 治仁, 大高 望, 竹内 英実, 辻 憲二, 田邊 克幸, 木野村 賢, 吉田 賢司, 前島 洋平, 杉山 斉, 伊藤 浩, 和田 淳

    日本腎臓学会誌   63 ( 4 )   474 - 474   2021.6

     More details

    Language:Japanese   Publisher:(一社)日本腎臓学会  

    researchmap

  • 岡山市CKDネットワーク(OCKD-NET)におけるCKD病診連携10年後の追跡調査

    大西 康博, 内田 治仁, 大高 望, 竹内 英実, 辻 憲二, 田邊 克幸, 森永 裕士, 木野村 賢, 喜多村 真治, 前島 洋平, 杉山 斉, 太田 康介, 丸山 啓輔, 大城 義之, 森岡 茂, 瀧上 慶一, 蒲生 直幸, 和田 淳

    日本腎臓学会誌   63 ( 4 )   513 - 513   2021.6

     More details

    Language:Japanese   Publisher:(一社)日本腎臓学会  

    researchmap

  • 人工知能による腎臓研究論文のテキストマイニングの検討

    喜多村 真治, 辻 憲二, 福島 和彦, 高橋 謙作, 桑 藝禎, 和田 淳

    日本腎臓学会誌   63 ( 4 )   448 - 448   2021.6

     More details

    Language:Japanese   Publisher:(一社)日本腎臓学会  

    researchmap

  • 成体腎臓幹細胞由来のエクソソームによる腎臓再生機序の解明と制御

    辻 憲二, 喜多村 真治, 和田 淳

    日本腎臓学会誌   63 ( 4 )   454 - 454   2021.6

     More details

    Language:Japanese   Publisher:(一社)日本腎臓学会  

    researchmap

  • 甲状腺機能低下症とCKDの関連性におけるCr代謝の影響についての検討

    内山 奈津実, 辻 憲二, 喜多村 真治, 稲垣 兼一, 内田 治仁, 杉山 斉, 和田 淳

    日本腎臓学会誌   63 ( 4 )   463 - 463   2021.6

     More details

    Language:Japanese   Publisher:(一社)日本腎臓学会  

    researchmap

  • 中四国地域におけるCKDおよびCVDの関連に関するコホート研究 Kakusyo 3C Studyのイベント解析

    大高 望, 内田 治仁, 竹内 英実, 辻 憲二, 田邊 克幸, 木野村 賢, 吉田 賢司, 前島 洋平, 杉山 斉, 伊藤 浩, 和田 淳

    日本腎臓学会誌   63 ( 4 )   464 - 464   2021.6

     More details

    Language:Japanese   Publisher:(一社)日本腎臓学会  

    researchmap

  • 人工知能(AI)による腎病理蛍光画像からの糖尿病性腎症の判別に関する検討

    喜多村 真治, 高橋 謙作, 福島 和彦, 辻 憲二, 和田 淳

    日本腎臓学会誌   62 ( 4 )   282 - 282   2020.7

     More details

    Language:Japanese   Publisher:(一社)日本腎臓学会  

    researchmap

  • 人工知能(AI)による血液透析患者のエポエチンαBS(BS)の腎性貧血治療反応予測プログラムの開発

    辻 憲二, 喜多村 真治, 高橋 謙作, 福島 和彦, 小林 直哉, 和田 淳

    日本腎臓学会誌   62 ( 4 )   352 - 352   2020.7

     More details

    Language:Japanese   Publisher:(一社)日本腎臓学会  

    researchmap

  • 中四国地域におけるCKDおよびCVDの関連に関する前向きコホート研究;Kakusyo 3C Study:登録3年後の中間解析

    大高 望, 内田 治仁, 西脇 麻里子, 辻 憲二, 北川 正史, 田邊 克幸, 木野村 賢, 吉田 賢司, 前島 洋平, 杉山 斉, 伊藤 浩, 和田 淳

    日本腎臓学会誌   62 ( 4 )   383 - 383   2020.7

     More details

    Language:Japanese   Publisher:(一社)日本腎臓学会  

    researchmap

  • 人工知能(AI)は血液透析患者のダルボポエチンαの糖尿病有無による腎性貧血治療抵抗性を予測する

    喜多村 真治, 高橋 謙作, 福島 和彦, 辻 憲二, 小林 直哉, 和田 淳

    日本腎臓学会誌   62 ( 4 )   352 - 352   2020.7

     More details

    Language:Japanese   Publisher:(一社)日本腎臓学会  

    researchmap

  • 人工知能(AI)は血液透析患者のエポエチンαBSの糖尿病有無による腎性貧血治療抵抗性を予測する

    辻 憲二, 喜多村 真治, 高橋 謙作, 福島 和彦, 小林 直哉, 和田 淳

    日本腎臓学会誌   62 ( 4 )   353 - 353   2020.7

     More details

    Language:Japanese   Publisher:(一社)日本腎臓学会  

    researchmap

  • 慢性腎臓病における貧血管理〜Kakusyo 3C Studyからの検討

    内山 奈津実, 内田 治仁, 西脇 麻里子, 大高 望, 辻 憲二, 北川 正史, 田邊 克幸, 木野村 賢, 吉田 賢司, 前島 洋平, 杉山 斉, 伊藤 浩, 和田 淳

    日本腎臓学会誌   62 ( 4 )   378 - 378   2020.7

     More details

    Language:Japanese   Publisher:(一社)日本腎臓学会  

    researchmap

  • 中四国地域におけるCKDおよびCVDの関連に関するコホート研究Kakusyo 3C Study:登録3年後のCKD管理状況

    西脇 麻里子, 内田 治仁, 大高 望, 辻 憲二, 北川 正史, 田邊 克幸, 木野村 賢, 吉田 賢司, 前島 洋平, 杉山 斉, 伊藤 浩, 和田 淳

    日本腎臓学会誌   62 ( 4 )   378 - 378   2020.7

     More details

    Language:Japanese   Publisher:(一社)日本腎臓学会  

    researchmap

  • 人工知能(AI)による血液透析患者のダルボポエチンαの入力項目による腎性貧血治療予測プログラムの検討

    高橋 謙作, 喜多村 真治, 福島 和彦, 辻 憲二, 小林 直哉, 和田 淳

    日本腎臓学会誌   62 ( 4 )   352 - 352   2020.7

     More details

    Language:Japanese   Publisher:(一社)日本腎臓学会  

    researchmap

  • 人工知能(AI)による血液透析患者のエポエチンαBSの入力項目による腎性貧血治療予測プログラムの検討

    福島 和彦, 喜多村 真治, 高橋 謙作, 辻 憲二, 小林 直哉, 和田 淳

    日本腎臓学会誌   62 ( 4 )   352 - 352   2020.7

     More details

    Language:Japanese   Publisher:(一社)日本腎臓学会  

    researchmap

  • Semaphorin3Aを介したポドサイト障害機序の解明

    辻 憲二, Yizhen Sang, 福島 和彦, 高橋 謙作, 喜多村 真治, 和田 淳

    日本腎臓学会誌   62 ( 4 )   310 - 310   2020.7

     More details

    Language:Japanese   Publisher:(一社)日本腎臓学会  

    researchmap

  • 岡山市CKDネットワーク(OCKD-NET)におけるCKD病診連携9年後の追跡調査

    大西 康博, 内田 治仁, 大高 望, 辻 憲二, 田邊 克幸, 森永 裕士, 木野村 賢, 喜多村 真治, 前島 洋平, 杉山 斉, 太田 康介, 丸山 啓輔, 大城 義之, 森岡 茂, 大森 一慶, 瀧上 慶一, 蒲生 直幸, 和田 淳

    日本腎臓学会誌   62 ( 4 )   307 - 307   2020.7

     More details

    Language:Japanese   Publisher:(一社)日本腎臓学会  

    researchmap

  • 人工知能(AI)による血液透析患者のダルボポエチンαの腎性貧血治療反応予測プログラムの開発

    喜多村 真治, 高橋 謙作, 福島 和彦, 辻 憲二, 小林 直哉, 和田 淳

    日本腎臓学会誌   62 ( 4 )   290 - 290   2020.7

     More details

    Language:Japanese   Publisher:(一社)日本腎臓学会  

    researchmap

  • AI(人工知能)による腎病理蛍光画像からのIgA腎症診断ツールの開発

    高橋 謙作, 喜多村 真治, 福島 和彦, 辻 憲二, 和田 淳

    日本腎臓学会誌   62 ( 4 )   271 - 271   2020.7

     More details

    Language:Japanese   Publisher:(一社)日本腎臓学会  

    researchmap

  • 尿中エクソソームおよび微小嚢胞中のmRNA測定による移植腎機能障害の診断法の開発および全国症例解析によるValidation

    原田 浩, 福澤 信之, 阿部 豊文, 今村 亮一, 正木 紀行, 藤山 信弘, 佐藤 滋, 畠山 真吾, 西村 憲二, 岸川 英史, 岩見 大基, 堀田 記世彦, 三浦 正義, 井手 健太郎, 中村 道郎, 香束 昌宏, 内田 潤次, 村上 卓, 辻 隆裕

    日本臨床腎移植学会雑誌   8 ( 1 )   142 - 150   2020.7

     More details

    Language:Japanese   Publisher:(一社)日本臨床腎移植学会  

    【研究目的】移植腎障害(KGI)を非侵襲的に診断しうるバイオマーカーの探索を尿中のエクソソーム・微小嚢胞(EV)中のmRNA解析により行った。【方法】全国11施設にて計127症例の腎移植後の尿検体を集めた。各尿検体からEV RNAを抽出し定量RT-PCR測定を行い、腎生検を含む病理診断結果と比較しマーカー候補遺伝子ならびに複数候補による診断式の診断性能を検証した。【結果】拒絶反応の鑑別では以前に報告したANXA1の上昇は確認できなかったものの、CXCL9、CXCL10、UMODがT細胞性拒絶反応(TCMR)で上昇し、慢性抗体関連拒絶反応(cABMR)ではSPNS2の上昇が確認された。Sparse Logistic Regression(SLR)解析による複数マーカー候補からなる診断式にてcABMRと他のKGI群とAUC 0.875で鑑別できることを確認した。また、臨床上判定が困難な慢性カルシニューリン毒性に比しても、SLR解析でAUC 0.886でcABMRの鑑別が可能であった。加えて、間質線維化・尿細管萎縮や慢性腎障害重症度と相関がみられるマーカー候補POTEMを確認し、SLR解析による診断式でおのおのAUC 0.830、0.850で鑑別できた。【結論】尿中EV RNA解析によりKGIを非侵襲的に診断できうる可能性を示した。(著者抄録)

    researchmap

    Other Link: https://search-tp.jamas.or.jp/index.php?module=Default&action=Link&pub_year=2020&ichushi_jid=J06262&link_issn=&doc_id=20200806480025&doc_link_id=%2Fem0sfcrt%2F2020%2F000801%2F025%2F0142-0150%26dl%3D0&url=https%3A%2F%2Fwww.medicalonline.jp%2Fjamas.php%3FGoodsID%3D%2Fem0sfcrt%2F2020%2F000801%2F025%2F0142-0150%26dl%3D0&type=MedicalOnline&icon=https%3A%2F%2Fjk04.jamas.or.jp%2Ficon%2F00004_2.gif

  • SGLT2阻害薬は肥満による腎障害において腎保護に寄与する

    福島 和彦, 喜多村 真治, 高橋 謙作, 桑 藝禎, 辻 憲二, 和田 淳

    日本腎臓学会誌   62 ( 4 )   263 - 263   2020.7

     More details

    Language:Japanese   Publisher:(一社)日本腎臓学会  

    researchmap

  • 【下降期慢性疾患患者の"具合"をよくする-ジェネラリストだからできること!】外来と在宅で診ている下降期慢性疾患 進行した慢性腎臓病 透析療法をしない場合の症状への対応 浮腫、食思不振等

    辻 憲二, 喜多村 真治, 和田 淳

    総合診療   30 ( 6 )   714 - 716   2020.6

  • 【下降期慢性疾患患者の"具合"をよくする-ジェネラリストだからできること!】外来と在宅で診ている下降期慢性疾患 進行した慢性腎臓病 薬物療法のコツ 降圧薬と利尿薬、高カリウム血症改善薬の使い方

    辻 憲二, 喜多村 真治, 和田 淳

    総合診療   30 ( 6 )   710 - 713   2020.6

     More details

    Language:Japanese   Publisher:(株)医学書院  

    <文献概要>慢性腎臓病(chronic kidney disease:以下、CKD)の進行に伴って、腎予備能が低下するとともに、高血圧、浮腫、高カリウム血症、貧血など、さまざまな異常所見が顕在化しやすく、それぞれが腎障害の加速因子となりうる。腎予後の改善や心血管合併症予防の観点から、臨床所見や検査データを基に、それぞれの病態に対して食事療法や薬剤療法を行い、厳格に管理する。

    researchmap

    Other Link: https://search-tp.jamas.or.jp/index.php?module=Default&action=Link&pub_year=2020&ichushi_jid=J06514&link_issn=&doc_id=20200612230027&doc_link_id=10.11477%2Fmf.1429202651&url=https%3A%2F%2Fdoi.org%2F10.11477%2Fmf.1429202651&type=%88%E3%8F%91.jp_%83I%81%5B%83%8B%83A%83N%83Z%83X&icon=https%3A%2F%2Fjk04.jamas.or.jp%2Ficon%2F00024_2.gif

  • Venous aneurysm(静脈性血管瘤)の臨床的検討

    近藤 肇彦, 中村 憲二, 鎌田 壽夫, 塩田 規帆, 上乃 誠, 辻 泰美, 竿尾 光祐

    回生病院医学雑誌   26   27 - 33   2020.3

     More details

    Language:Japanese   Publisher:(社医財)大樹会総合病院回生病院  

    静脈性血管瘤(VA)は無症状で経過することが多く、炎症や血栓を形成して血栓性静脈炎や致命的な肺塞栓症(PE)をきたす事があり、注目されている。2011年1月〜2019年3月に当院で経験した静脈性血管瘤(VA)症例を対象に、臨床的検討を行った。当院で経験したVA症例は8例で、男性は3例、女性は5例であった。年齢は39〜84歳で、平均59歳であった。発生部位は、上肢3例、腹壁1例、下肢4例であった。病型分類は2種類あり、嚢胞状タイプ(Sacciform)がI型、紡錘状タイプ(Fusiform)がII型である。I型が4例、II型が4例であった。全例手術治療を行い、全摘出術を行った。術後経過も全例順調で特別問題となった症例はなかった。本稿では、84歳女性、49歳男性、47歳女性の症例について詳述した。

    researchmap

  • AI(人工知能)による腎病理蛍光画像からのIgA腎症診断ツールの開発

    高橋 謙作, 喜多村 真治, 福島 和彦, 辻 憲二, 和田 淳

    日本内科学会雑誌   109 ( Suppl. )   244 - 244   2020.2

     More details

    Language:Japanese   Publisher:(一社)日本内科学会  

    researchmap

  • 免疫チェックポイント阻害薬投与中に甲状腺機能低下に伴う一過性の腎機能低下を認めた一例

    当真 貴志雄, 稲垣 兼一, 松岡 奈津実, 辻 憲二, 西山 悠紀, 藤澤 諭, 原 孝行, 越智 可奈子, 和田 淳

    日本内分泌学会雑誌   95 ( 4 )   1352 - 1352   2020.2

     More details

    Language:Japanese   Publisher:(一社)日本内分泌学会  

    researchmap

  • 人工知能(AI)による腎病理蛍光画像からの糖尿病性腎症の判別に関する検討

    福島 和彦, 喜多村 真治, 高橋 謙作, 辻 憲二, 和田 淳

    日本内科学会雑誌   109 ( Suppl. )   173 - 173   2020.2

     More details

    Language:Japanese   Publisher:(一社)日本内科学会  

    researchmap

  • 人工知能(AI)による血液透析患者のエポエチンαBSの腎性貧血治療反応予測プログラムの開発

    辻憲二, 喜多村真治, 高橋謙作, 福島和彦, 小林直哉, 和田淳

    日本透析医学会雑誌   53 ( Supplement 1 )   809 - 809   2020

     More details

    Language:Japanese   Publisher:(一社)日本透析医学会  

    J-GLOBAL

    researchmap

  • 腎不全療法選択説明が緊急透析導入と療法選択に与える影響

    森永裕士, 笠原由美子, 井本紀子, 角川紫野, 矢田光子, 大高望, 辻憲二, 北川正史, 田邊克幸, 木野村賢, 喜多村真治, 内田治仁, 杉山斉, 和田淳

    日本透析医学会雑誌   53 ( Supplement 1 )   496 - 496   2020

     More details

    Language:Japanese   Publisher:(一社)日本透析医学会  

    J-GLOBAL

    researchmap

  • 人工知能(AI)は血液透析患者のエポエチンαBSの糖尿病有無による腎性貧血治療反応差を予測する

    辻憲二, 喜多村真治, 高橋謙作, 福島和彦, 小林直哉, 和田淳

    日本透析医学会雑誌   53 ( Supplement 1 )   808 - 808   2020

     More details

    Language:Japanese   Publisher:(一社)日本透析医学会  

    J-GLOBAL

    researchmap

  • ステロイドの早期減量後に再燃したIgM陽性形質細胞を伴う尿細管間質性腎炎の2例

    松岡 奈津実, 辻 憲二, 中村 嶺, 杉山 斉, 高橋 直生, 岩野 正之

    日本腎臓学会誌   61 ( 6 )   892 - 892   2019.8

     More details

    Language:Japanese   Publisher:(一社)日本腎臓学会  

    researchmap

  • 中四国地域におけるCKDおよびCVDの関連に関するコホート研究Kakusyo 3C Study 登録2年後のCKD管理状況

    西脇 麻里子, 内田 治仁, 大高 望, 大西 章史, 辻 憲二, 北川 正史, 田邊 克幸, 木野村 賢, 吉田 賢司, 前島 洋平, 杉山 斉, 伊藤 浩, 和田 淳

    日本腎臓学会誌   61 ( 3 )   419 - 419   2019.5

     More details

    Language:Japanese   Publisher:(一社)日本腎臓学会  

    researchmap

  • 中四国地域におけるCKDおよびCVDの関連に関するコホート研究 Kakusyo 3C Study 登録2年後の中間解析

    大高 望, 内田 治仁, 大西 章史, 辻 憲二, 北川 正史, 田邊 克幸, 木野村 賢, 吉田 賢司, 前島 洋平, 杉山 斉, 伊藤 浩, 和田 淳

    日本腎臓学会誌   61 ( 3 )   418 - 418   2019.5

     More details

    Language:Japanese   Publisher:(一社)日本腎臓学会  

    researchmap

  • 慢性腎臓病における貧血管理 Kakusyo 3C Studyからの検討

    松岡 奈津実, 内田 治仁, 大高 望, 大西 章史, 辻 憲二, 北川 正史, 田邊 克幸, 木野村 賢, 吉田 賢司, 前島 洋平, 杉山 斉, 伊藤 浩, 和田 淳

    日本腎臓学会誌   61 ( 3 )   407 - 407   2019.5

     More details

    Language:Japanese   Publisher:(一社)日本腎臓学会  

    researchmap

  • SGLT2阻害薬はメタボリックシンドロームにおいて腎保護に寄与する

    福島 和彦, 喜多村 真治, 辻 憲二, 桑 藝禎, 和田 淳

    日本腎臓学会誌   61 ( 3 )   294 - 294   2019.5

     More details

    Language:Japanese   Publisher:(一社)日本腎臓学会  

    researchmap

  • 腹膜透析患者における腹膜機能廃絶重症化防止のための新たな腹膜機能検査の開発

    辻 憲二, 喜多村 真治, 杉山 斉, 槇野 博史

    中国腎不全研究会誌   21   307 - 308   2012.12

     More details

    Language:Japanese   Publisher:(一社)中国腎不全研究会  

    researchmap

  • A case of chronic renal failure with adrenal insufficiency from adrenal tuberculosis

    2009   518 - 522   2009

     More details

▼display all

Presentations

  • 人工知能による腎臓研究論文のテキストマイニングの検討

    喜多村 真治, 辻 憲二, 福島 和彦, 高橋 謙作, 桑 藝禎, 和田 淳

    日本腎臓学会誌  2021.6  (一社)日本腎臓学会

     More details

    Event date: 2021.6

    Language:Japanese  

    researchmap

  • 岡山市CKDネットワーク(OCKD-NET)におけるCKD病診連携10年後の追跡調査

    大西 康博, 内田 治仁, 大高 望, 竹内 英実, 辻 憲二, 田邊 克幸, 森永 裕士, 木野村 賢, 喜多村 真治, 前島 洋平, 杉山 斉, 太田 康介, 丸山 啓輔, 大城 義之, 森岡 茂, 瀧上 慶一, 蒲生 直幸, 和田 淳

    日本腎臓学会誌  2021.6  (一社)日本腎臓学会

     More details

    Event date: 2021.6

    Language:Japanese  

    researchmap

  • 慢性腎臓病における貧血管理 Kakusyo 3C Studyからの検討

    奥山 由加, 内田 治仁, 大高 望, 竹内 英実, 辻 憲二, 田邊 克幸, 木野村 賢, 吉田 賢司, 前島 洋平, 杉山 斉, 伊藤 浩, 和田 淳

    日本腎臓学会誌  2021.6  (一社)日本腎臓学会

     More details

    Event date: 2021.6

    Language:Japanese  

    researchmap

  • 甲状腺機能低下症とCKDの関連性におけるCr代謝の影響についての検討

    内山 奈津実, 辻 憲二, 喜多村 真治, 稲垣 兼一, 内田 治仁, 杉山 斉, 和田 淳

    日本腎臓学会誌  2021.6  (一社)日本腎臓学会

     More details

    Event date: 2021.6

    Language:Japanese  

    researchmap

  • 成体腎臓幹嚢胞由来のエクソソームによる腎臓再生機序の解明と制御

    辻 憲二, 喜多村 真治, 和田 淳

    日本腎臓学会誌  2021.6  (一社)日本腎臓学会

     More details

    Event date: 2021.6

    Language:Japanese  

    researchmap

  • 人工知能による症例報告のテキストマイニングの検討

    喜多村 真治, 辻 憲二, 福島 和彦, 高橋 謙作, 桑 藝禎, 和田 淳

    日本腎臓学会誌  2021.6  (一社)日本腎臓学会

     More details

    Event date: 2021.6

    Language:Japanese  

    researchmap

  • 中四国地域におけるCKDおよびCVDの関連に関するコホート研究 Kakusyo 3C Studyのイベント解析

    大高 望, 内田 治仁, 竹内 英実, 辻 憲二, 田邊 克幸, 木野村 賢, 吉田 賢司, 前島 洋平, 杉山 斉, 伊藤 浩, 和田 淳

    日本腎臓学会誌  2021.6  (一社)日本腎臓学会

     More details

    Event date: 2021.6

    Language:Japanese  

    researchmap

  • 甲状腺機能低下症とCKDの関連性におけるCr代謝の影響についての検討

    内山奈津実, 辻憲二, 喜多村真治, 稲垣兼一, 内田治仁, 杉山斉, 和田淳

    日本腎臓学会誌(Web)  2021 

     More details

    Event date: 2021

    researchmap

  • 中四国地域におけるCKDおよびCVDの関連に関するコホート研究;Kakusyo3C Studyのイベント解析

    大高望, 内田治仁, 竹内英実, 辻憲二, 田邊克幸, 木野村賢, 吉田賢司, 前島洋平, 杉山斉, 伊藤浩, 和田淳

    日本腎臓学会誌(Web)  2021 

     More details

    Event date: 2021

    researchmap

  • 人工知能による腎臓研究論文のテキストマイニングの検討

    喜多村真治, 辻憲二, 福島和彦, 高橋謙作, 桑藝禎, 和田淳

    日本腎臓学会誌(Web)  2021 

     More details

    Event date: 2021

    researchmap

  • 人工知能による症例報告のテキストマイニングの検討

    喜多村真治, 辻憲二, 福島和彦, 高橋謙作, 桑藝禎, 和田淳

    日本腎臓学会誌(Web)  2021 

     More details

    Event date: 2021

    researchmap

  • 岡山市CKDネットワーク(OCKD-NET)におけるCKD病診連携10年後の追跡調査

    大西康博, 内田治仁, 大高望, 竹内英実, 辻憲二, 田邊克幸, 森永裕士, 木野村賢, 喜多村真治, 前島洋平, 杉山斉, 太田康介, 丸山啓輔, 大城義之, 森岡茂, 瀧上慶一, 蒲生直幸, 和田淳

    日本腎臓学会誌(Web)  2021 

     More details

    Event date: 2021

    researchmap

  • 慢性腎臓病における貧血管理~Kakusyo3C Studyからの検討

    奥山由加, 内田治仁, 大高望, 竹内英実, 辻憲二, 田邊克幸, 木野村賢, 吉田賢司, 前島洋平, 杉山斉, 伊藤浩, 和田淳

    日本腎臓学会誌(Web)  2021 

     More details

    Event date: 2021

    researchmap

  • 成体腎臓幹細胞由来のエクソソームによる腎臓再生機序の解明と制御

    辻憲二, 喜多村真治, 和田淳

    日本腎臓学会誌(Web)  2021 

     More details

    Event date: 2021

    researchmap

  • 腎不全療法選択説明が緊急透析導入と療法選択に与える影響

    森永 裕士, 笠原 由美子, 井本 紀子, 角川 紫野, 矢田 光子, 大高 望, 辻 憲二, 北川 正史, 田邊 克幸, 木野村 賢, 喜多村 真治, 内田 治仁, 杉山 斉, 和田 淳

    日本透析医学会雑誌  2020.10  (一社)日本透析医学会

     More details

    Event date: 2020.10

    Language:Japanese  

    researchmap

  • 人工知能(AI)による血液透析患者のエポエチンαBSの腎性貧血治療反応予測プログラムの開発

    辻 憲二, 喜多村 真治, 高橋 謙作, 福島 和彦, 小林 直哉, 和田 淳

    日本透析医学会雑誌  2020.10  (一社)日本透析医学会

     More details

    Event date: 2020.10

    Language:Japanese  

    researchmap

  • 人工知能(AI)は血液透析患者のエポエチンαBSの糖尿病有無による腎性貧血治療反応差を予測する

    辻 憲二, 喜多村 真治, 高橋 謙作, 福島 和彦, 小林 直哉, 和田 淳

    日本透析医学会雑誌  2020.10  (一社)日本透析医学会

     More details

    Event date: 2020.10

    Language:Japanese  

    researchmap

  • 岡山市CKDネットワーク(OCKD-NET)におけるCKD病診連携9年後の追跡調査

    大西 康博, 内田 治仁, 大高 望, 辻 憲二, 田邊 克幸, 森永 裕士, 木野村 賢, 喜多村 真治, 前島 洋平, 杉山 斉, 太田 康介, 丸山 啓輔, 大城 義之, 森岡 茂, 大森 一慶, 瀧上 慶一, 蒲生 直幸, 和田 淳

    日本腎臓学会誌  2020.7  (一社)日本腎臓学会

     More details

    Event date: 2020.7

    Language:Japanese  

    researchmap

  • 人工知能(AI)は血液透析患者のダルボポエチンαの糖尿病有無による腎性貧血治療抵抗性を予測する

    喜多村 真治, 高橋 謙作, 福島 和彦, 辻 憲二, 小林 直哉, 和田 淳

    日本腎臓学会誌  2020.7  (一社)日本腎臓学会

     More details

    Event date: 2020.7

    Language:Japanese  

    researchmap

  • 人工知能(AI)による血液透析患者のエポエチンαBSの入力項目による腎性貧血治療予測プログラムの検討

    福島 和彦, 喜多村 真治, 高橋 謙作, 辻 憲二, 小林 直哉, 和田 淳

    日本腎臓学会誌  2020.7  (一社)日本腎臓学会

     More details

    Event date: 2020.7

    Language:Japanese  

    researchmap

  • 人工知能(AI)は血液透析患者のエポエチンαBSの糖尿病有無による腎性貧血治療抵抗性を予測する

    辻 憲二, 喜多村 真治, 高橋 謙作, 福島 和彦, 小林 直哉, 和田 淳

    日本腎臓学会誌  2020.7  (一社)日本腎臓学会

     More details

    Event date: 2020.7

    Language:Japanese  

    researchmap

  • Semaphorin3Aを介したポドサイト障害機序の解明

    辻 憲二, Yizhen Sang, 福島 和彦, 高橋 謙作, 喜多村 真治, 和田 淳

    日本腎臓学会誌  2020.7  (一社)日本腎臓学会

     More details

    Event date: 2020.7

    Language:Japanese  

    researchmap

  • 岡山市CKDネットワーク(OCKD-NET)におけるCKD病診連携9年後の追跡調査

    大西 康博, 内田 治仁, 大高 望, 辻 憲二, 田邊 克幸, 森永 裕士, 木野村 賢, 喜多村 真治, 前島 洋平, 杉山 斉, 太田 康介, 丸山 啓輔, 大城 義之, 森岡 茂, 大森 一慶, 瀧上 慶一, 蒲生 直幸, 和田 淳

    日本腎臓学会誌  2020.7  (一社)日本腎臓学会

     More details

    Event date: 2020.7

    Language:Japanese  

    researchmap

  • 人工知能(AI)による血液透析患者のダルボポエチンαの入力項目による腎性貧血治療予測プログラムの検討

    高橋 謙作, 喜多村 真治, 福島 和彦, 辻 憲二, 小林 直哉, 和田 淳

    日本腎臓学会誌  2020.7  (一社)日本腎臓学会

     More details

    Event date: 2020.7

    Language:Japanese  

    researchmap

  • 人工知能(AI)による血液透析患者のエポエチンαBS(BS)の腎性貧血治療反応予測プログラムの開発

    辻 憲二, 喜多村 真治, 高橋 謙作, 福島 和彦, 小林 直哉, 和田 淳

    日本腎臓学会誌  2020.7  (一社)日本腎臓学会

     More details

    Event date: 2020.7

    Language:Japanese  

    researchmap

  • 中四国地域におけるCKDおよびCVDの関連に関するコホート研究Kakusyo 3C Study:登録3年後のCKD管理状況

    西脇 麻里子, 内田 治仁, 大高 望, 辻 憲二, 北川 正史, 田邊 克幸, 木野村 賢, 吉田 賢司, 前島 洋平, 杉山 斉, 伊藤 浩, 和田 淳

    日本腎臓学会誌  2020.7  (一社)日本腎臓学会

     More details

    Event date: 2020.7

    Language:Japanese  

    researchmap

  • 慢性腎臓病における貧血管理〜Kakusyo 3C Studyからの検討

    内山 奈津実, 内田 治仁, 西脇 麻里子, 大高 望, 辻 憲二, 北川 正史, 田邊 克幸, 木野村 賢, 吉田 賢司, 前島 洋平, 杉山 斉, 伊藤 浩, 和田 淳

    日本腎臓学会誌  2020.7  (一社)日本腎臓学会

     More details

    Event date: 2020.7

    Language:Japanese  

    researchmap

  • 中四国地域におけるCKDおよびCVDの関連に関する前向きコホート研究;Kakusyo 3C Study:登録3年後の中間解析

    大高 望, 内田 治仁, 西脇 麻里子, 辻 憲二, 北川 正史, 田邊 克幸, 木野村 賢, 吉田 賢司, 前島 洋平, 杉山 斉, 伊藤 浩, 和田 淳

    日本腎臓学会誌  2020.7  (一社)日本腎臓学会

     More details

    Event date: 2020.7

    Language:Japanese  

    researchmap

  • 慢性腎臓病における貧血管理〜Kakusyo 3C Studyからの検討

    内山 奈津実, 内田 治仁, 西脇 麻里子, 大高 望, 辻 憲二, 北川 正史, 田邊 克幸, 木野村 賢, 吉田 賢司, 前島 洋平, 杉山 斉, 伊藤 浩, 和田 淳

    日本腎臓学会誌  2020.7  (一社)日本腎臓学会

     More details

    Event date: 2020.7

    Language:Japanese  

    researchmap

  • 人工知能(AI)は血液透析患者のエポエチンαBSの糖尿病有無による腎性貧血治療抵抗性を予測する

    辻 憲二, 喜多村 真治, 高橋 謙作, 福島 和彦, 小林 直哉, 和田 淳

    日本腎臓学会誌  2020.7  (一社)日本腎臓学会

     More details

    Event date: 2020.7

    Language:Japanese  

    researchmap

  • SGLT2阻害薬は肥満による腎障害において腎保護に寄与する

    福島 和彦, 喜多村 真治, 高橋 謙作, 桑 藝禎, 辻 憲二, 和田 淳

    日本腎臓学会誌  2020.7  (一社)日本腎臓学会

     More details

    Event date: 2020.7

    Language:Japanese  

    researchmap

  • 中四国地域におけるCKDおよびCVDの関連に関するコホート研究Kakusyo 3C Study:登録3年後のCKD管理状況

    西脇 麻里子, 内田 治仁, 大高 望, 辻 憲二, 北川 正史, 田邊 克幸, 木野村 賢, 吉田 賢司, 前島 洋平, 杉山 斉, 伊藤 浩, 和田 淳

    日本腎臓学会誌  2020.7  (一社)日本腎臓学会

     More details

    Event date: 2020.7

    Language:Japanese  

    researchmap

  • 人工知能(AI)による血液透析患者のダルボポエチンαの入力項目による腎性貧血治療予測プログラムの検討

    高橋 謙作, 喜多村 真治, 福島 和彦, 辻 憲二, 小林 直哉, 和田 淳

    日本腎臓学会誌  2020.7  (一社)日本腎臓学会

     More details

    Event date: 2020.7

    Language:Japanese  

    researchmap

  • 人工知能(AI)による血液透析患者のエポエチンαBS(BS)の腎性貧血治療反応予測プログラムの開発

    辻 憲二, 喜多村 真治, 高橋 謙作, 福島 和彦, 小林 直哉, 和田 淳

    日本腎臓学会誌  2020.7  (一社)日本腎臓学会

     More details

    Event date: 2020.7

    Language:Japanese  

    researchmap

  • 人工知能(AI)は血液透析患者のダルボポエチンαの糖尿病有無による腎性貧血治療抵抗性を予測する

    喜多村 真治, 高橋 謙作, 福島 和彦, 辻 憲二, 小林 直哉, 和田 淳

    日本腎臓学会誌  2020.7  (一社)日本腎臓学会

     More details

    Event date: 2020.7

    Language:Japanese  

    researchmap

  • 人工知能(AI)による血液透析患者のエポエチンαBSの入力項目による腎性貧血治療予測プログラムの検討

    福島 和彦, 喜多村 真治, 高橋 謙作, 辻 憲二, 小林 直哉, 和田 淳

    日本腎臓学会誌  2020.7  (一社)日本腎臓学会

     More details

    Event date: 2020.7

    Language:Japanese  

    researchmap

  • AI(人工知能)による腎病理蛍光画像からのIgA腎症診断ツールの開発

    高橋 謙作, 喜多村 真治, 福島 和彦, 辻 憲二, 和田 淳

    日本腎臓学会誌  2020.7  (一社)日本腎臓学会

     More details

    Event date: 2020.7

    Language:Japanese  

    researchmap

  • 人工知能(AI)による血液透析患者のダルボポエチンαの腎性貧血治療反応予測プログラムの開発

    喜多村 真治, 高橋 謙作, 福島 和彦, 辻 憲二, 小林 直哉, 和田 淳

    日本腎臓学会誌  2020.7  (一社)日本腎臓学会

     More details

    Event date: 2020.7

    Language:Japanese  

    researchmap

  • 人工知能(AI)による腎病理蛍光画像からの糖尿病性腎症の判別に関する検討

    喜多村 真治, 高橋 謙作, 福島 和彦, 辻 憲二, 和田 淳

    日本腎臓学会誌  2020.7  (一社)日本腎臓学会

     More details

    Event date: 2020.7

    Language:Japanese  

    researchmap

  • SGLT2阻害薬は肥満による腎障害において腎保護に寄与する

    福島 和彦, 喜多村 真治, 高橋 謙作, 桑 藝禎, 辻 憲二, 和田 淳

    日本腎臓学会誌  2020.7  (一社)日本腎臓学会

     More details

    Event date: 2020.7

    Language:Japanese  

    researchmap

  • 人工知能(AI)による腎病理蛍光画像からの糖尿病性腎症の判別に関する検討

    喜多村 真治, 高橋 謙作, 福島 和彦, 辻 憲二, 和田 淳

    日本腎臓学会誌  2020.7  (一社)日本腎臓学会

     More details

    Event date: 2020.7

    Language:Japanese  

    researchmap

  • AI(人工知能)による腎病理蛍光画像からのIgA腎症診断ツールの開発

    高橋 謙作, 喜多村 真治, 福島 和彦, 辻 憲二, 和田 淳

    日本腎臓学会誌  2020.7  (一社)日本腎臓学会

     More details

    Event date: 2020.7

    Language:Japanese  

    researchmap

  • 人工知能(AI)による血液透析患者のダルボポエチンαの腎性貧血治療反応予測プログラムの開発

    喜多村 真治, 高橋 謙作, 福島 和彦, 辻 憲二, 小林 直哉, 和田 淳

    日本腎臓学会誌  2020.7  (一社)日本腎臓学会

     More details

    Event date: 2020.7

    Language:Japanese  

    researchmap

  • Semaphorin3Aを介したポドサイト障害機序の解明

    辻 憲二, Yizhen Sang, 福島 和彦, 高橋 謙作, 喜多村 真治, 和田 淳

    日本腎臓学会誌  2020.7  (一社)日本腎臓学会

     More details

    Event date: 2020.7

    Language:Japanese  

    researchmap

  • Venous aneurysm(静脈性血管瘤)の臨床的検討

    近藤 肇彦, 中村 憲二, 鎌田 壽夫, 塩田 規帆, 上乃 誠, 辻 泰美, 竿尾 光祐

    回生病院医学雑誌  2020.3  (社医財)大樹会総合病院回生病院

     More details

    Event date: 2020.3

    Language:Japanese  

    静脈性血管瘤(VA)は無症状で経過することが多く、炎症や血栓を形成して血栓性静脈炎や致命的な肺塞栓症(PE)をきたす事があり、注目されている。2011年1月〜2019年3月に当院で経験した静脈性血管瘤(VA)症例を対象に、臨床的検討を行った。当院で経験したVA症例は8例で、男性は3例、女性は5例であった。年齢は39〜84歳で、平均59歳であった。発生部位は、上肢3例、腹壁1例、下肢4例であった。病型分類は2種類あり、嚢胞状タイプ(Sacciform)がI型、紡錘状タイプ(Fusiform)がII型である。I型が4例、II型が4例であった。全例手術治療を行い、全摘出術を行った。術後経過も全例順調で特別問題となった症例はなかった。本稿では、84歳女性、49歳男性、47歳女性の症例について詳述した。

    researchmap

  • 人工知能(AI)による腎病理蛍光画像からの糖尿病性腎症の判別に関する検討

    福島 和彦, 喜多村 真治, 高橋 謙作, 辻 憲二, 和田 淳

    日本内科学会雑誌  2020.2  (一社)日本内科学会

     More details

    Event date: 2020.2

    Language:Japanese  

    researchmap

  • AI(人工知能)による腎病理蛍光画像からのIgA腎症診断ツールの開発

    高橋 謙作, 喜多村 真治, 福島 和彦, 辻 憲二, 和田 淳

    日本内科学会雑誌  2020.2  (一社)日本内科学会

     More details

    Event date: 2020.2

    Language:Japanese  

    researchmap

  • 人工知能(AI)は血液透析患者のエポエチンαBSの糖尿病有無による腎性貧血治療抵抗性を予測する

    辻憲二, 喜多村真治, 高橋謙作, 福島和彦, 小林直哉, 和田淳

    日本腎臓学会誌(Web)  2020 

     More details

    Event date: 2020

    researchmap

  • 人工知能(AI)による血液透析患者のエポエチンαBS(BS)の腎性貧血治療反応予測プログラムの開発

    辻憲二, 喜多村真治, 高橋謙作, 福島和彦, 小林直哉, 和田淳

    日本腎臓学会誌(Web)  2020 

     More details

    Event date: 2020

    researchmap

  • 人工知能(AI)による血液透析患者のダルボポエチンαの腎性貧血治療反応予測プログラムの開発

    喜多村真治, 高橋謙作, 福島和彦, 辻憲二, 小林直哉, 和田淳

    日本腎臓学会誌(Web)  2020 

     More details

    Event date: 2020

    researchmap

  • 人工知能(AI)による腎病理蛍光画像からの糖尿病性腎症の判別に関する検討

    喜多村真治, 高橋謙作, 福島和彦, 辻憲二, 和田淳

    日本腎臓学会誌(Web)  2020 

     More details

    Event date: 2020

    researchmap

  • 慢性腎臓病における貧血管理~Kakusyo3C Studyからの検討

    内山奈津実, 内田治仁, 西脇麻里子, 大高望, 辻憲二, 北川正史, 田邊克幸, 木野村賢, 吉田賢司, 前島洋平, 杉山斉, 伊藤浩, 和田淳

    日本腎臓学会誌(Web)  2020 

     More details

    Event date: 2020

    researchmap

  • 人工知能(AI)による血液透析患者のエポエチンαBSの入力項目による腎性貧血治療予測プログラムの検討

    福島和彦, 喜多村真治, 高橋謙作, 辻憲二, 小林直哉, 和田淳

    日本腎臓学会誌(Web)  2020 

     More details

    Event date: 2020

    researchmap

  • 中四国地域におけるCKDおよびCVDの関連に関するコホート研究Kakusyo3C Study:登録3年後のCKD管理状況

    西脇麻里子, 内田治仁, 大高望, 辻憲二, 北川正史, 田邊克幸, 木野村賢, 吉田賢司, 前島洋平, 杉山斉, 伊藤浩, 和田淳

    日本腎臓学会誌(Web)  2020 

     More details

    Event date: 2020

    researchmap

  • 岡山市CKDネットワーク(OCKD-NET)におけるCKD病診連携9年後の追跡調査

    大西康博, 内田治仁, 大高望, 辻憲二, 田邊克幸, 森永裕士, 木野村賢, 喜多村真治, 前島洋平, 杉山斉, 太田康介, 丸山啓輔, 大城義之, 森岡茂, 大森一慶, 瀧上慶一, 蒲生直幸, 和田淳

    日本腎臓学会誌(Web)  2020 

     More details

    Event date: 2020

    researchmap

  • 中四国地域におけるCKDおよびCVDの関連に関する前向きコホート研究;Kakusyo3C Study:登録3年後の中間解析

    大高望, 内田治仁, 西脇麻里子, 辻憲二, 北川正史, 田邊克幸, 木野村賢, 吉田賢司, 前島洋平, 杉山斉, 伊藤浩, 和田淳

    日本腎臓学会誌(Web)  2020 

     More details

    Event date: 2020

    researchmap

  • SGLT2阻害薬は肥満による腎障害において腎保護に寄与する

    福島和彦, 喜多村真治, 高橋謙作, 桑藝禎, 辻憲二, 和田淳

    日本腎臓学会誌(Web)  2020 

     More details

    Event date: 2020

    researchmap

  • AI(人工知能)による腎病理蛍光画像からのIg A腎症診断ツールの開発

    高橋謙作, 喜多村真治, 福島和彦, 辻憲二, 和田淳

    日本腎臓学会誌(Web)  2020 

     More details

    Event date: 2020

    researchmap

  • Podocytopathyで発症した全身性エリテマトーデスの一例

    高津瑶子, 辻憲二, 片山祐, 大宮照明, 杉山斉, 和田淳

    日本腎臓学会誌(Web)  2020 

     More details

    Event date: 2020

    researchmap

  • 人工知能(AI)による血液透析患者のダルボポエチンαの入力項目による腎性貧血治療予測プログラムの検討

    高橋謙作, 喜多村真治, 福島和彦, 辻憲二, 小林直哉, 和田淳

    日本腎臓学会誌(Web)  2020 

     More details

    Event date: 2020

    researchmap

  • Semaphorin3Aを介したポドサイト障害機序の解明

    辻憲二, SANG Yizhen, 福島和彦, 高橋謙作, 喜多村真治, 和田淳

    日本腎臓学会誌(Web)  2020 

     More details

    Event date: 2020

    researchmap

  • 人工知能(AI)は血液透析患者のダルボポエチンαの糖尿病有無による腎性貧血治療抵抗性を予測する

    喜多村真治, 高橋謙作, 福島和彦, 辻憲二, 小林直哉, 和田淳

    日本腎臓学会誌(Web)  2020 

     More details

    Event date: 2020

    researchmap

  • 下降期慢性疾患患者の“具合”をよくする ジェネラリストだからできること!外来と在宅で診ている下降期慢性疾患 3.進行した慢性腎臓病 5)透析療法をしない場合の症状への対応 浮腫,食思不振等

    辻憲二, 喜多村真治, 和田淳

    総合診療  2020  (株)医学書院

  • 下降期慢性疾患患者の“具合”をよくする ジェネラリストだからできること!外来と在宅で診ている下降期慢性疾患 3.進行した慢性腎臓病 4)薬物療法のコツ 降圧薬と利尿薬,高カリウム血症改善薬の使い方

    辻憲二, 喜多村真治, 和田淳

    総合診療  2020  (株)医学書院

     More details

    Event date: 2020

    Language:Japanese  

    <文献概要>慢性腎臓病(chronic kidney disease:以下、CKD)の進行に伴って、腎予備能が低下するとともに、高血圧、浮腫、高カリウム血症、貧血など、さまざまな異常所見が顕在化しやすく、それぞれが腎障害の加速因子となりうる。腎予後の改善や心血管合併症予防の観点から、臨床所見や検査データを基に、それぞれの病態に対して食事療法や薬剤療法を行い、厳格に管理する。

    researchmap

    Other Link: https://search.jamas.or.jp/index.php?module=Default&action=Link&pub_year=2020&ichushi_jid=J06514&link_issn=&doc_id=20200612230027&doc_link_id=10.11477%2Fmf.1429202651&url=https%3A%2F%2Fdoi.org%2F10.11477%2Fmf.1429202651&type=%88%E3%8F%91.jp_%83I%81%5B%83%8B%83A%83N%83Z%83X&icon=https%3A%2F%2Fjk04.jamas.or.jp%2Ficon%2F00024_2.gif

  • AI(人工知能)による腎病理蛍光画像からのIgA腎症診断ツールの開発

    高橋謙作, 喜多村真治, 福島和彦, 辻憲二, 和田淳

    日本内科学会雑誌  2020  (一社)日本内科学会

     More details

    Event date: 2020

    Language:Japanese  

    researchmap

  • 人工知能(AI)による腎病理蛍光画像からの糖尿病性腎症の判別に関する検討

    福島和彦, 喜多村真治, 高橋謙作, 辻憲二, 和田淳

    日本内科学会雑誌  2020  (一社)日本内科学会

     More details

    Event date: 2020

    Language:Japanese  

    researchmap

  • 腎臓領域における人工知能(AI)研究の展開

    喜多村真治, 高橋謙作, 福島和彦, 辻憲二, 和田淳

    日本腎臓学会誌(Web)  2020 

     More details

    Event date: 2020

    researchmap

  • 慢性腎臓病における貧血管理 Kakusyo 3C Studyからの検討

    松岡 奈津実, 内田 治仁, 大高 望, 大西 章史, 辻 憲二, 北川 正史, 田邊 克幸, 木野村 賢, 吉田 賢司, 前島 洋平, 杉山 斉, 伊藤 浩, 和田 淳

    日本腎臓学会誌  2019.5  (一社)日本腎臓学会

     More details

    Event date: 2019.5

    Language:Japanese  

    researchmap

  • SGLT2阻害薬はメタボリックシンドロームにおいて腎保護に寄与する

    福島 和彦, 喜多村 真治, 辻 憲二, 桑 藝禎, 和田 淳

    日本腎臓学会誌  2019.5  (一社)日本腎臓学会

     More details

    Event date: 2019.5

    Language:Japanese  

    researchmap

  • 中四国地域におけるCKDおよびCVDの関連に関するコホート研究Kakusyo 3C Study 登録2年後のCKD管理状況

    西脇 麻里子, 内田 治仁, 大高 望, 大西 章史, 辻 憲二, 北川 正史, 田邊 克幸, 木野村 賢, 吉田 賢司, 前島 洋平, 杉山 斉, 伊藤 浩, 和田 淳

    日本腎臓学会誌  2019.5  (一社)日本腎臓学会

     More details

    Event date: 2019.5

    Language:Japanese  

    researchmap

  • 中四国地域におけるCKDおよびCVDの関連に関するコホート研究 Kakusyo 3C Study 登録2年後の中間解析

    大高 望, 内田 治仁, 大西 章史, 辻 憲二, 北川 正史, 田邊 克幸, 木野村 賢, 吉田 賢司, 前島 洋平, 杉山 斉, 伊藤 浩, 和田 淳

    日本腎臓学会誌  2019.5  (一社)日本腎臓学会

     More details

    Event date: 2019.5

    Language:Japanese  

    researchmap

  • 免疫チェックポイント阻害薬投与中に甲状腺機能低下に伴う一過性の腎機能低下を認めた一例

    当真貴志雄, 稲垣兼一, 松岡奈津実, 辻憲二, 西山悠紀, 藤澤諭, 原孝行, 越智可奈子, 和田淳

    日本内分泌学会雑誌  2019  (一社)日本内分泌学会

     More details

    Event date: 2019

    Language:Japanese  

    researchmap

  • 慢性腎臓病における貧血管理~Kakusyo 3C Studyからの検討

    松岡奈津実, 内田治仁, 大高望, 大西章史, 辻憲二, 北川正史, 田邊克幸, 木野村賢, 吉田賢司, 前島洋平, 杉山斉, 伊藤浩, 和田淳

    日本腎臓学会誌  2019 

     More details

    Event date: 2019

    Language:Japanese  

    researchmap

  • SGLT2阻害薬はメタボリックシンドロームにおいて腎保護に寄与する

    福島和彦, 喜多村真治, 辻憲二, 桑藝禎, 和田淳

    日本腎臓学会誌  2019 

     More details

    Event date: 2019

    Language:Japanese  

    researchmap

  • 中四国地域におけるCKDおよびCVDの関連に関するコホート研究Kakusyo 3C Study:登録2年後のCKD管理状況

    西脇麻里子, 内田治仁, 大高望, 大西章史, 辻憲二, 北川正史, 田邊克幸, 木野村賢, 吉田賢司, 前島洋平, 杉山斉, 伊藤浩, 和田淳

    日本腎臓学会誌  2019 

     More details

    Event date: 2019

    Language:Japanese  

    researchmap

  • ステロイドの早期減量後に再燃したIgM陽性形質細胞を伴う尿細管間質性腎炎の2例

    松岡奈津実, 辻憲二, 中村嶺, 杉山斉, 高橋直生, 岩野正之

    日本腎臓学会誌  2019  (一社)日本腎臓学会

     More details

    Event date: 2019

    Language:Japanese  

    researchmap

  • 中四国地域におけるCKDおよびCVDの関連に関するコホート研究;Kakusyo 3C Study:登録2年後の中間解析

    大高望, 内田治仁, 大西章史, 辻憲二, 北川正史, 田邊克幸, 木野村賢, 吉田賢司, 前島洋平, 杉山斉, 伊藤浩, 和田淳

    日本腎臓学会誌  2019 

     More details

    Event date: 2019

    Language:Japanese  

    researchmap

  • SECRET FACTORS FROM ADULT KIDNEY STEM/PROGENITOR CELLS CONTRIBUTE TO REGENERATION

    Tsuji Kenji, Kitamura Shinji, Inoue Akiko, Makino Hirofumi

    NEPHROLOGY  2014.5  WILEY-BLACKWELL

     More details

    Event date: 2014.5

    Language:English  

    researchmap

  • 尿中Semaphorin3Aは微小変化型ネフローゼ症候群の活動性を反映する

    井上 章子, 辻 憲二, 前島 洋平, 杉山 斉, 喜多村 真治

    日本腎臓学会誌  2014  (一社)日本腎臓学会

     More details

    Event date: 2014

    Language:Japanese  

    researchmap

  • 成体腎臓幹/前駆細胞の分泌因子による再生機序の解明

    辻 憲二, 井上 章子, 前島 洋平, 杉山 斉, 喜多村 真治

    日本腎臓学会誌  2014  (一社)日本腎臓学会

     More details

    Event date: 2014

    Language:Japanese  

    researchmap

  • 成体腎臓幹/前駆細胞による分泌因子を介した間接的な再生機序の解明

    辻憲二, 喜多村真治, 井上章子, 槇野博史

    再生医療  2014 

     More details

    Event date: 2014

    Language:Japanese  

    researchmap

  • 腹膜透析患者への腹膜機能重症化防止を目指した腹膜再生療法

    喜多村 真治, 辻 憲二, 堀元 直哉, 杉山 斉, 槇野 博史

    日本透析医学会雑誌 = Journal of Japanese Society for Dialysis Therapy  2013.2.28  一般社団法人 日本透析医学会

     More details

    Event date: 2013.2.28

    Language:Japanese  

    researchmap

  • 腹膜再生と腹膜透析治療modality 腹膜透析患者への腹膜機能重症化防止を目指した腹膜再生療法

    喜多村 真治, 辻 憲二, 堀元 直哉, 杉山 斉, 槇野 博史

    日本透析医学会雑誌  2013.2  (一社)日本透析医学会

     More details

    Event date: 2013.2

    Language:Japanese  

    researchmap

  • 急性腎不全で発症し透析を離脱し得たSLEの1例

    大西 章史, 森永 裕士, 赤木 滋, 北川 正史, 井上 章子, 寺見 直人, 山成 俊夫, 辻 憲二, 氏家 はる代, 小川 愛由, 中山 和典, 綿谷 博雪, 井上 淳子, 田邊 克幸, 杉山 斉, 槇野 博史

    日本腎臓学会誌  2013  (一社)日本腎臓学会

     More details

    Event date: 2013

    Language:Japanese  

    researchmap

  • 5. 腹膜透析患者への腹膜機能重症化防止を目指した腹膜再生療法

    喜多村真治, 辻憲二, 堀元直哉, 杉山斉, 槇野博史

    日本透析医学会雑誌  2013 

     More details

    Event date: 2013

    Language:Japanese  

    researchmap

  • Hypoxia-inducible factor(HIF)は尿管芽細胞増殖を介さずに尿管芽分岐を促進する

    辻 憲二, 喜多村 真治, 前島 洋平, 杉山 斉, 槇野 博史

    日本腎臓学会誌  2013  (一社)日本腎臓学会

     More details

    Event date: 2013

    Language:Japanese  

    researchmap

  • 成体腎臓幹/前駆細胞からの腎臓再構築時における経時的な遺伝子発現の検討

    喜多村 真治, 辻 憲二, 槇野 博史

    日本腎臓学会誌  2013  (一社)日本腎臓学会

     More details

    Event date: 2013

    Language:Japanese  

    researchmap

  • 寛解中に後天性血友病Aを発症した微小変化型ネフローゼ症候群の一例

    野島 一郎, 瀧上 慶一, 安富 絵里子, 西部 倫之, 中嶋 崇文, 辻 憲二, 池田 直人, 久保西 四郎, 杉山 斉

    日本腎臓学会誌  2013  (一社)日本腎臓学会

     More details

    Event date: 2013

    Language:Japanese  

    researchmap

  • MPO-ANCA関連腎炎と膜性腎症を合併した3症例の検討

    益田 加奈, 内田 治仁, 細谷 武史, 林 啓悟, 辻 憲二, 小川 愛由, 氏家 はる代, 梅林 亮子, 喜多村 真治, 前島 洋平, 杉山 斉, 槇野 博史

    日本腎臓学会誌  2013  (一社)日本腎臓学会

     More details

    Event date: 2013

    Language:Japanese  

    researchmap

  • 培養ヒト腹膜中皮細胞上清を使用した腹膜障害重症化防止効果についての検討

    堀元直哉, 喜多村真治, 辻憲二, 杉山斉, 槇野博史

    日本腎臓学会誌  2012  (一社)日本腎臓学会

     More details

    Event date: 2012

    Language:Japanese  

    researchmap

  • 成体腎臓幹/前駆細胞を使用した腎臓再構築の機能解析:尿細管機能を中心に

    喜多村真治, 辻憲二, 堀元直哉, 槇野博史

    日本腎臓学会誌  2012  (一社)日本腎臓学会

     More details

    Event date: 2012

    Language:Japanese  

    researchmap

  • 腎臓発生過程におけるHIF‐1αとGDNF/RET pathwayとの関連性の検討

    辻憲二, 喜多村真治, 堀元直哉, 前島洋平, 杉山斉, 槇野博史

    日本腎臓学会誌  2012  (一社)日本腎臓学会

     More details

    Event date: 2012

    Language:Japanese  

    researchmap

  • 腹膜透析患者における腹膜機能廃絶重症化防止のための新たな腹膜機能検査の開発

    辻 憲二, 喜多村 真治, 杉山 斉, 槇野 博史

    中国腎不全研究会誌  2012  中国腎不全研究会

     More details

    Event date: 2012

    Language:Japanese  

    researchmap

  • 意識障害が持続し,診断に難渋した急性散在性脳脊髄炎(ADEM)の透析患者の1例

    萩山容子, 石崎淳, 辻憲二, 茎田奈央子, 蒲生直幸, 西村誠明, 奥田真也, 冨田仁美, 岡本憲省, 奥田文悟

    愛媛県立病院学会々誌  2011  愛媛県公営企業管理局県立病院課

     More details

    Event date: 2011

    Language:Japanese  

    59歳男。糖尿病性腎症のため腹膜透析で維持透析を受けていた。今回、発熱、感冒症状の後に意識レベル低下、痙攣発作が出現し、頭部CTで異常なく、髄液検査よりヘルペス脳炎を疑い治療を開始した。しかし、発熱、痙攣発作、四肢不随意運動が持続して当院救急入院となった。脳波、髄液、血液検査所見より無菌性脊髄炎、単純ヘルペス脳炎と診断し、アシクロビル、メロペン、献血ベニロン、グリセオールおよび免疫グロブリンの治療を開始した。また、腹膜透析は継続しながら、溢水管理のため週1回の血液透析を併用した。治療後、単核球優位の細胞数増多を認めた髄液所見は改善し、痙攣発作も消失したが、意識障害、四肢不随意運動は持続し、急性散在性脳脊髄炎を疑いMRIを施行したところ、大脳白質、右優位に線条体に散在性の高信号域を認め診断を確定した。ステロイドパルス療法(ソル・メドロール1000mg/日×3)を開始したところ、急速に意識レベルは改善して四肢不随意運動も消失し、その後のMRIでは高信号域の軽減を認めた。全身状態が安定した後、近医転院となった。

    researchmap

  • 膜性増殖性糸球体腎炎と低γグロブリン血症の経過中に巣状糸球体硬化症を併発した1例

    辻憲二, 内田治仁, 小野哲一郎, 喜多村真治, 前島洋平, 杉山斉, 槇野博史

    日本腎臓学会誌  2011  (一社)日本腎臓学会

     More details

    Event date: 2011

    Language:Japanese  

    researchmap

  • TIA後に脳梗塞を発症しt‐PA投与が著効した高齢者心原性塞栓症の1症例

    山本有希, 川田好高, 鈴木誠, 風谷幸男, 辻憲二, 鴨川賢二, 岡本憲省, 奥田文吾

    日本老年医学会雑誌  2010  (一社)日本老年医学会

     More details

    Event date: 2010

    Language:Japanese  

    researchmap

  • Small arteries showed vasculitis in the renal biopsy of ANCA associated autopsy case.

    嶋本純也, 石崎淳, 辻憲二, 蒲生直幸, 西村誠明, 古谷敬三

    愛媛県立病院学会々誌  2010  愛媛県公営企業管理局県立病院課

     More details

    Event date: 2010

    Language:Japanese  

    83歳男。患者は咳嗽があり近医を受診、間質性肺炎と診断され、ブレドニゾロンの内服が開始されたものの、発熱および倦怠感が出現し、あわせて尿異常、炎症反応高値、MPO(myeloperoxidase)-ANCA(anti-neutrophil cytoplasmic autoantibody)陽性が認められた。今回、腎生検目的にて、著者らの施設へ紹介となったが、所見では糸球体に半月体形成はみられなかったものの、小葉間動脈に血管炎像が認められ、MPA(microscopic polyangitis)と診断された。治療はステロイドパルス療法施行後にプレドニゾロンの投与が開始されたが、血管炎腎外病変である間質性肺炎の増悪と感染のコントロールに難渋し、最終的に呼吸状態の悪化により患者は死亡となった。尚、剖検所見では腎臓は小葉間動脈領域の内膜の断裂、線維性肥厚狭小化がみられたが、血管周囲のリンパ節浸潤は軽度であり、血管炎瘢痕期と考えられた。また、死因としては間質性肺炎の増悪が推察された。

    researchmap

  • 当院における高齢者ネフローゼ症候群の病理学的検討

    安田麻衣子, 辻憲二, 石崎淳, 茎田奈央子, 蒲生直幸, 西村誠明

    愛媛県立病院学会々誌  2010  愛媛県公営企業管理局県立病院課

     More details

    Event date: 2010

    Language:Japanese  

    著者らは腎生検を施行した70歳以上の高齢者ネフローゼ症候群33症例(平均年齢74歳)を対象に病理学的検討を行った。1)続発性ネフローゼ症候群34%と他施設の報告とには差はなかったが、一方で原発性ネフローゼ症候群は膜性腎症の割合が多いとされているものの、微小変化群が多く認められた。また、腎機能低下症例も多く認められた。2)20例でステロイド治療が開始され、4例でネフローゼ症候群から溢水によって心不全を呈し一時的に透析を必要とした。3)治療開始から3ヵ月後に52%、1年後に73%の症例に治療効果が確認され、高齢者であっても積極的な治療によって腎予後、生命予後の改善が期待できる症例の存在が示唆された。4)死亡は経過中8例にみられ、最終的に透析導入となった腎死症例が4例に認められた。5)腎生検による重大な合併症は認められなかったが、ネフローゼ症候群による合併症は感染症を7例、深部静脈血栓症を1例、出血性潰瘍を2例に確認された。尚、悪性腫瘍の合併は10例に認められた。

    researchmap

  • IgG4関連疾患の3症例

    西村誠明, 茎田奈央子, 那須達世, 蒲生直幸, 辻憲二, 塚本尚子

    日本腎臓学会誌  2010  (一社)日本腎臓学会

     More details

    Event date: 2010

    Language:Japanese  

    researchmap

  • IgA腎症における扁桃腺摘出及びステロイドパルス療法とステロイド及び多剤併用療法の治療効果に関する検討

    蒲生直幸, 辻憲二, 石崎淳, 茎田奈央子, 西村誠明

    日本腎臓学会誌  2009.8.25  (一社)日本腎臓学会

     More details

    Event date: 2009.8.25

    Language:Japanese  

    researchmap

  • ネフローゼ症候群を呈した混合性結合組織病の2症例

    石崎淳, 辻憲二, 茎田奈央子, 蒲生直幸, 西村誠明

    日本腎臓学会誌  2009.8.25  (一社)日本腎臓学会

     More details

    Event date: 2009.8.25

    Language:Japanese  

    researchmap

  • 副腎結核による副腎不全を合併した慢性腎不全の1例

    茎田奈央子, 石崎淳, 辻憲二, 蒲生直幸, 西村誠明, 堀見孔星, 西村謙一, 篠森健介, 仙崎智一, 藤方史朗, 二宮郁, 岡本賢二郎

    腎と透析  2009.5.25  (株)東京医学社

     More details

    Event date: 2009.5.25

    Language:Japanese  

    60歳女。1年4ヵ月前にCAPD導入し、APDにて維持していた。今回、微熱と汎血球減少症が出現し、結核性骨髄炎と診断して治療中、副腎結核による副腎不全を合併した。抗結核薬4剤による治療とヒドロコルチゾンの内服により結核、副腎不全とも改善したが、抗結核薬の副作用が強く治療に難渋した。また副腎結核の診断では組織検査で結核菌が検出されず、悪性腫瘍との鑑別のために副腎摘出を要した。

    researchmap

  • 透析患者における後腹膜鏡下根治的腎摘除術の検討

    谷本修二, 由良健太郎, 堀見孔星, 西村謙一, 仙崎智一, 篠森健介, 藤方史朗, 二宮郁, 岡本賢二郎, 山師定, 菅政治, 石崎淳, 辻憲二, 蒲生直幸, 西村誠明

    日本透析医学会雑誌  2009.5.8  (一社)日本透析医学会

     More details

    Event date: 2009.5.8

    Language:Japanese  

    researchmap

  • A case of chronic renal failure with adrenal insufficiency from adrenal tuberculosis

    茎田 奈央子, 石崎 淳, 辻 憲二

    腹膜透析  2009  東京医学社

     More details

    Event date: 2009

    Language:Japanese  

    researchmap

  • 腹膜透析3年目に難治性腹膜炎により被嚢性腹膜硬化症を併発し,CAPDを断念した一例

    辻憲二, 石崎淳, 茎田奈央子, 蒲生直幸, 西村誠明, 由良健太郎, 堀見孔星, 西村謙一, 篠森健介, 仙崎智一, 藤方史朗, 二宮郁, 谷本修二, 岡本賢二郎, 山師定, 菅政治

    日本透析医学会雑誌  2009  (一社)日本透析医学会

     More details

    Event date: 2009

    Language:Japanese  

    researchmap

  • 多関節痛,発熱,胸部異常影にて発症し,P‐ANCA・抗CCP抗体陽性の半月体形成型腎炎の一例

    西村誠明, 辻憲二, 石崎淳, 蒲生直幸

    日本腎臓学会誌  2008.8.25  (一社)日本腎臓学会

     More details

    Event date: 2008.8.25

    Language:Japanese  

    researchmap

  • 妊娠中に子癇発作と思われる痙攣発作が出現し発見された褐色細胞腫の1例

    辻憲二, 中村舞, 新谷哲司, 井上靖浩, 玉木みずね, 大野敬三, 清水一紀

    日本内分泌学会雑誌  2008.3.20  (一社)日本内分泌学会

     More details

    Event date: 2008.3.20

    Language:Japanese  

    researchmap

  • 血球貪食症候群を合併した糖尿病性腎症による慢性腎不全の1例

    茎田奈央子, 石崎淳, 辻憲二, 蒲生直幸, 西村誠明, 堀見孔星, 西村謙一, 篠森健介, 仙崎智一, 藤方史朗, 布川朋也, 二宮郁, 岡本賢二郎, 山師定, 菅政治, 大岡啓二

    日本透析医学会雑誌  2008  (一社)日本透析医学会

     More details

    Event date: 2008

    Language:Japanese  

    researchmap

  • 短期間で食事療法で改善する2型糖尿病患者の背景

    辻憲二, 茎田奈央子, 新谷哲司, 井上靖浩, 大野敬三, 玉木みずね, 清水一紀

    糖尿病  2008  (一社)日本糖尿病学会

     More details

    Event date: 2008

    Language:Japanese  

    researchmap

▼display all

Awards

  • 第18回村川・難波技術奨励賞

    2023.5   山陽技術振興会  

     More details

  • 2021年度 JSWN症例報告論文賞 受賞指導

    2022.7  

    松岡奈津実先生

     More details

  • 第57回山陽放送学術文化財団 学術奨励賞

    2020.5  

     More details

  • CKD Frontier Award (受賞指導)

    2020.2   SM-345431 Ameliorates Doxorubicin-induced Podocyte Injury

     More details

  • 優秀演題賞(受賞指導)

    2019.10   第48回日本腎臓学会西部学術大会   ステロイドの早期減量後に再燃したIgM陽性形質細胞を伴った尿細管間質性腎炎の2例

     More details

  • 第43回四国透析療法研究会学術症例賞

    2009  

     More details

▼display all

Research Projects

  • 腎臓線維化におけるSemaphorin3A経路の病態機序の解明と治療への応用

    Grant number:24K11411  2024.04 - 2027.03

    日本学術振興会  科学研究費助成事業  基盤研究(C)

    辻 憲二

      More details

    Authorship:Principal investigator 

    Grant amount:\4550000 ( Direct expense: \3500000 、 Indirect expense:\1050000 )

    researchmap

  • シミュレーション教育を活用した人材育成システムの開発

    2023.12 - 2024.11

    カシオ科学振興財団  第41回(令和5年度)研究助成 

      More details

    Authorship:Principal investigator 

    researchmap

  • 成体腎臓幹細胞由来の腎臓オルガノイドを用いた新たな薬剤評価法の樹立

    2023.07 - 2024.06

    ウエスコ学術振興財団  令和5年度学術研究費助成 

      More details

    Authorship:Principal investigator 

    researchmap

  • 医学生における超音波ガイド針生検シミュレーション教育の有用性についての検討

    2023.04 - 2024.03

    医学教育振興財団  医学教育研究助成(令和5年度) 

      More details

    Authorship:Principal investigator 

    researchmap

  • スチレン系軟質樹脂を用いた実用可能な腎生検模擬モデルの開発

    2022.12 - 2023.11

    岡山医学振興会  医学教育研究助成 

      More details

    Authorship:Principal investigator 

    researchmap

  • Semaphorin3A(SEMA3A)を標的とした腎線維化を制御する革新的治療開発

    2022.09 - 2024.08

    カイオムバイオサイエンス株式会社 

      More details

  • HIF-PH阻害による成体腎臓幹細胞を介した腎臓再生機序の解明

    2021.05 - 2023.03

    田辺三菱製薬株式会社 

      More details

  • Elucidation of pathophysiology of idiopathic nephrotic syndrome by microRNA analysis and development of novel therapeutic agents

    Grant number:20K17283  2020.04 - 2024.03

    Japan Society for the Promotion of Science  Grants-in-Aid for Scientific Research Grant-in-Aid for Early-Career Scientists  Grant-in-Aid for Early-Career Scientists

    辻 憲二

      More details

    Grant amount:\4160000 ( Direct expense: \3200000 、 Indirect expense:\960000 )

    本研究は、特発性ネフローゼ症候群について、エクソソーム内のマイクロ(micro)RNAの観点から新たな病態機序解明を行うものである。特発性ネフローゼ症候群(巣状分節性糸球体硬化症/微小変化型ネフローゼ症候群)患者血清よりエクソソームを抽出しエクソソーム内の因子が病態に関与することをin vivo及びin vitroにおいて評価し、さらに患者血清エクソソームより抽出したmicroRNAの解析により疾患特異的に変化するmicroRNAをリストアップし、それらのmicroRNAmimicを作成してin vivoおよびin vitroの系を用いて糸球体上皮細胞障害を呈する疾患特異的なmicroRNAの特定を目指している。特発性ネフローゼ症候群患者及び対照群より採取した血清よりTIM4法を用いたエクソソーム抽出キットを用いてエクソソームを抽出した。抽出エクソソームを透過型電子顕微鏡を用いて評価し、純度の高いエクソソーム抽出を確認した。また、エクソソーム特異的抗体を用いたイムノブロット法により抽出エクソソーム分画におけるCD63及びCD9の陽性及びグリセルアルデヒド-3-リン酸デヒドロゲナーゼ(GAPDH)の陰性を確認した。以上より純度の高いエクソソーム抽出に成功したと考えられた。
    現在ネフローゼ症候群症例の検体を収集しつつ、抽出したエクソソームを用いたmicroRNAの解析及びin vivo及びin vitroの系における病態への関連についての検討を進めていく。

    researchmap

  • 慢性腎臓病におけるSemaphorin3Aを標的とした腎線維化の制御

    2020.04 - 2021.03

    石橋由紀子記念基金令和元年研究助成 

      More details

  • Semaphroin3A阻害剤による腎線維化の制御

    2020.04 - 2021.03

    山陽放送学術文化財団学術研究助成金 

      More details

  • 腎臓病におけるSemaphorin3Aを介した腎線維化の制御

    Grant number:2019-9  2020.02 - 2022.02

    日本透析医学会研究助成 

      More details

  • 成体腎臓幹細胞を用いた新たな腎性貧血治療の開発

    Grant number:JKFB19-4  2019.12 - 2021.03

    日本腎臓財団 腎不全病態研究助成 

      More details

  • 腎臓成体幹細胞由来エキソソームの腎臓再生機序の解明

    2019.04 - 2020.03

    一般財団法人 寺岡記念育英会研究助成 

      More details

  • ループス腎炎におけるSemaphorin3Aのマクロファージを介した病態機序解明

    2018.11 - 2021.03

    GSKジャパン 

      More details

  • The elucidation of the pathological mechanism of semaphorin3a in glomerular podocyte injury

    Grant number:18K15978  2018.04 - 2021.03

    Japan Society for the Promotion of Science  Grants-in-Aid for Scientific Research  Grant-in-Aid for Early-Career Scientists

    Tsuji Kenji

      More details

    Grant amount:\4160000 ( Direct expense: \3200000 、 Indirect expense:\960000 )

    In this study, we identified that the upregulation of Semaphorin3A in glomerular epithelial cells is involved in the development of glomerular epithelial cell damage. In a mouse model of Adriamycin-induced glomerular epithelial cell injury, we identified that the increased expression of Semaphorin3A in glomerular epithelial cells induces apoptosis, and that the disorder is alleviated by a Semaphorin3A inhibitor.

    researchmap

  • Elucidation the mechanism of progression on peritoneal sclerosis in peritoneal dialysis

    Grant number:26461252  2014.04 - 2018.03

    Japan Society for the Promotion of Science  Grants-in-Aid for Scientific Research Grant-in-Aid for Scientific Research (C)  Grant-in-Aid for Scientific Research (C)

    KITAMURA SHINJI, TSUJI KENZI, TORII AKIKO

      More details

    Grant amount:\4810000 ( Direct expense: \3700000 、 Indirect expense:\1110000 )

    In Vitro study, peritoneal mesothelial cells were performed the morphological and qualitative evaluation. The cells used were peritoneal mesothelial cells, with cobblestone morphologic cells (Epi cells) and fibroblast-like peritoneal mesothelial cells (Fib cells). From the result, it is suggested that Fib cells play an important role in peritoneal sclerosis although Epi cells change poorly not only in acidic stimulation but also in sugar stimulation.
    In vivo study, Epi cell supernatant significantly improved peritoneal damage and peritoneal adhesion compared to the peritoneal sclerosis positive model, however in Fib cell supernatants, peritoneal deterioration were significantly observed. From these results, it is suggested that secreted factor from peritoneal mesothelial cells is also important. We will also conduct exosome analysis in secreted factors to aim for elucidation of its mechanism.

    researchmap

▼display all

 

Class subject in charge

  • Immunology (2023academic year) special  - その他

  • Endocrinology and Metabolism (2023academic year) special  - その他

  • Internal Medicine (3)(Core Clinical Practice) (2023academic year) special  - その他

  • Immunology (2022academic year) special  - その他

  • Endocrinology and Metabolism (2022academic year) special  - その他

  • Internal Medicine (3)(Core Clinical Practice) (2022academic year) special  - その他

  • Immunology (2021academic year) special  - その他

  • Endocrinology and Metabolism (2021academic year) special  - その他

  • Internal Medicine (3)(Core Clinical Practice) (2021academic year) special  - その他

  • Immunology (2020academic year) special  - その他

  • Endocrinology and Metabolism (2020academic year) special  - その他

  • Internal Medicine (3)(Core Clinical Practice) (2020academic year) special  - その他

▼display all

 

Academic Activities

  • Guest editor in Diagnostics for special issue "Recent Advances in Diagnosis and Treatment of Kidney Diseases." : 2nd Edition.

    Role(s):Supervision (editorial)

    2024.1.26

     More details

  • Diagnostics: 2024 Travel Awards Committee

    Role(s):Review, evaluation

    2024.1

     More details

  • Guest editor in Diagnostics for special issue "Recent Advances in Diagnosis and Treatment of Kidney Diseases."

    Role(s):Supervision (editorial)

    2023.2.17 - 2023.12.31

     More details

  • Advisory Board of Diagnostics (ISSN 2075-4418)

    2022.11

     More details

    Type:Peer review 

    researchmap